<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">78636</article-id><article-id pub-id-type="doi">10.7554/eLife.78636</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>Gallbladder adenocarcinomas undergo subclonal diversification and selection from precancerous lesions to metastatic tumors</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-273904"><name><surname>Kang</surname><given-names>Minsu</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6491-2277</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-273905"><name><surname>Na</surname><given-names>Hee Young</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-273906"><name><surname>Ahn</surname><given-names>Soomin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1979-4010</contrib-id><email>suminy317@gmail.com</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-273298"><name><surname>Kim</surname><given-names>Ji-Won</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6426-9074</contrib-id><email>jiwonkim@snubh.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-273907"><name><surname>Lee</surname><given-names>Sejoon</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273908"><name><surname>Ahn</surname><given-names>Soyeon</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273909"><name><surname>Lee</surname><given-names>Ju Hyun</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273910"><name><surname>Youk</surname><given-names>Jeonghwan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273911"><name><surname>Kim</surname><given-names>Haesook T</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273912"><name><surname>Kim</surname><given-names>Kui-Jin</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273913"><name><surname>Suh</surname><given-names>Koung Jin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273914"><name><surname>Lee</surname><given-names>Jun Suh</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273915"><name><surname>Kim</surname><given-names>Se Hyun</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2292-906X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273916"><name><surname>Kim</surname><given-names>Jin Won</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273917"><name><surname>Kim</surname><given-names>Yu Jung</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273918"><name><surname>Lee</surname><given-names>Keun-Wook</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273919"><name><surname>Yoon</surname><given-names>Yoo-Seok</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273920"><name><surname>Kim</surname><given-names>Jee Hyun</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273921"><name><surname>Chung</surname><given-names>Jin-Haeng</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273922"><name><surname>Han</surname><given-names>Ho-Seong</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273923"><name><surname>Lee</surname><given-names>Jong Seok</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00cb3km46</institution-id><institution>Department of Internal Medicine, Seoul National University Bundang Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Seongnam</named-content></addr-line><country>Republic of Korea</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00cb3km46</institution-id><institution>Department of Pathology, Seoul National University Bundang Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Seongnam</named-content></addr-line><country>Republic of Korea</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05a15z872</institution-id><institution>Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Seoul</named-content></addr-line><country>Republic of Korea</country></aff><aff id="aff4"><label>4</label><institution>Genealogy Inc</institution><addr-line><named-content content-type="city">Seoul</named-content></addr-line><country>Republic of Korea</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00cb3km46</institution-id><institution>Center for Precision Medicine, Seoul National University Bundang Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Seongnam</named-content></addr-line><country>Republic of Korea</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00cb3km46</institution-id><institution>Medical Research Collaboration Center, Seoul National University Bundang Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Seongnam</named-content></addr-line><country>Republic of Korea</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02jzgtq86</institution-id><institution>Department of Data Science, Dana Farber Cancer Institute, Harvard T.H. Chan School of Public Health</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00cb3km46</institution-id><institution>Biomedical Research Institute, Seoul National University Bundang Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Seongnam</named-content></addr-line><country>Republic of Korea</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00cb3km46</institution-id><institution>Department of Surgery, Seoul National University Bundang Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Seongnam</named-content></addr-line><country>Republic of Korea</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Turajlic</surname><given-names>Samra</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04tnbqb63</institution-id><institution>The Francis Crick Institute</institution></institution-wrap><country>United Kingdom</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Rathmell</surname><given-names>W Kimryn</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05dq2gs74</institution-id><institution>Vanderbilt University Medical Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>08</day><month>12</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e78636</elocation-id><history><date date-type="received" iso-8601-date="2022-03-14"><day>14</day><month>03</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-12-06"><day>06</day><month>12</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-04-01"><day>01</day><month>04</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.03.31.486530"/></event></pub-history><permissions><copyright-statement>© 2022, Kang, Na et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Kang, Na et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-78636-v3.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-78636-figures-v3.pdf"/><abstract><p>We aimed to elucidate the evolutionary trajectories of gallbladder adenocarcinoma (GBAC) using multi-regional and longitudinal tumor samples. Using whole-exome sequencing data, we constructed phylogenetic trees in each patient and analyzed mutational signatures. A total of 11 patients including 2 rapid autopsy cases were enrolled. The most frequently altered gene in primary tumors was <italic>ERBB2</italic> and <italic>TP53</italic> (54.5%), followed by <italic>FBXW7</italic> (27.3%). Most mutations in frequently altered genes in primary tumors were detectable in concurrent precancerous lesions (biliary intraepithelial neoplasia [BilIN]), but a substantial proportion was subclonal. Subclonal diversity was common in BilIN (n=4). However, among subclones in BilIN, a certain subclone commonly shrank in concurrent primary tumors. In addition, selected subclones underwent linear and branching evolution, maintaining subclonal diversity. Combined analysis with metastatic tumors (n=11) identified branching evolution in nine patients (81.8%). Of these, eight patients (88.9%) had a total of 11 subclones expanded at least sevenfold during metastasis. These subclones harbored putative metastasis-driving mutations in cancer-related genes such as <italic>SMAD4</italic>, <italic>ROBO1</italic>, and <italic>DICER1</italic>. In mutational signature analysis, six mutational signatures were identified: 1, 3, 7, 13, 22, and 24 (cosine similarity &gt;0.9). Signatures 1 (age) and 13 (APOBEC) decreased during metastasis while signatures 22 (aristolochic acid) and 24 (aflatoxin) were relatively highlighted. Subclonal diversity arose early in precancerous lesions and clonal selection was a common event during malignant transformation in GBAC. However, selected cancer clones continued to evolve and thus maintained subclonal diversity in metastatic tumors.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>gallbladder adenocarcinoma</kwd><kwd>clonal evolution</kwd><kwd>carcinogenesis</kwd><kwd>metastasis</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>Seoul National University Bundang Hospital Research Fund</institution></institution-wrap></funding-source><award-id>No. 16-2021-001</award-id><principal-award-recipient><name><surname>Kim</surname><given-names>Ji-Won</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>Small Grant for Exploratory Reserach</institution></institution-wrap></funding-source><award-id>NRF-2018R1D1A1A02086240</award-id><principal-award-recipient><name><surname>Kim</surname><given-names>Ji-Won</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>As the first to track clonal evolution from precancerous to metastatic lesions in gallbladder cancer patients, spatial and temporal analyses reveal how subclonal diversity in precancerous stage changes toward the metastasis, which help early detection and effective treatment of cancer.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Gallbladder adenocarcinoma (GBAC) is a malignant neoplasm that has a high incidence rate in Chile, India, Poland, Pakistan, Japan, and Korea (<xref ref-type="bibr" rid="bib45">Roa et al., 2022</xref>; <xref ref-type="bibr" rid="bib53">Valle et al., 2021</xref>; <xref ref-type="bibr" rid="bib3">Bray et al., 2018</xref>; <xref ref-type="bibr" rid="bib4">Bridgewater et al., 2014</xref>). Surgery is currently the only curative treatment modality for GBAC. However, because most patients are diagnosed at an advanced stage and thus inoperable, they receive palliative chemotherapy only. Therefore, the prognosis is poor with a median overall survival of only 11–15 months (<xref ref-type="bibr" rid="bib45">Roa et al., 2022</xref>; <xref ref-type="bibr" rid="bib53">Valle et al., 2021</xref>; <xref ref-type="bibr" rid="bib52">Valle et al., 2010</xref>).</p><p>The recent advancement of massively parallel sequencing technology has enabled us to deeply understand the genome of a variety of cancers. In GBAC, tumor suppressor genes such as <italic>TP53</italic>, <italic>ARID1A,</italic> and <italic>SMAD4</italic> and oncogenes such as <italic>ERBB2</italic> (<italic>HER2</italic>), <italic>ERBB3</italic>, and <italic>PIK3CA</italic> are significantly mutated (<xref ref-type="bibr" rid="bib45">Roa et al., 2022</xref>; <xref ref-type="bibr" rid="bib41">Nepal et al., 2021</xref>; <xref ref-type="bibr" rid="bib55">Wardell et al., 2018</xref>; <xref ref-type="bibr" rid="bib31">Li et al., 2019</xref>; <xref ref-type="bibr" rid="bib37">Nakamura et al., 2015</xref>; <xref ref-type="bibr" rid="bib32">Lin et al., 2021</xref>; <xref ref-type="bibr" rid="bib40">Narayan et al., 2019</xref>; <xref ref-type="bibr" rid="bib30">Li et al., 2014</xref>). Of note, <italic>ERBB2</italic> amplification and overexpression occur in approximately 6.9–28.6% of GBAC (<xref ref-type="bibr" rid="bib45">Roa et al., 2022</xref>; <xref ref-type="bibr" rid="bib40">Narayan et al., 2019</xref>; <xref ref-type="bibr" rid="bib38">Nakazawa et al., 2005</xref>; <xref ref-type="bibr" rid="bib39">Nam et al., 2016</xref>) and may have therapeutic implications.</p><p>Cancer cells undergo clonal evolution by acquiring additional mutations and thus exhibit more aggressive phenotypes, including invasion and metastasis (<xref ref-type="bibr" rid="bib50">Turajlic et al., 2019</xref>; <xref ref-type="bibr" rid="bib17">Greaves and Maley, 2012</xref>; <xref ref-type="bibr" rid="bib9">Davis et al., 2017</xref>). Several large-scale studies have provided evidence of clonal evolution in some cancer types, including lung and kidney cancers (<xref ref-type="bibr" rid="bib23">Jamal-Hanjani et al., 2017</xref>; <xref ref-type="bibr" rid="bib49">Turajlic et al., 2018</xref>). However, no study has analyzed the patterns of clonal evolution from the initiation of carcinogenesis to distant metastasis in patients with GBAC.</p><p>This study aims to analyze the clonal evolutionary trajectories during carcinogenesis and metastasis of GBAC using multi-regional and longitudinal specimens including precancerous lesions (biliary intraepithelial neoplasia [BilIN]), primary tumors, and metastatic tumors from patients who underwent biopsy, surgery, and rapid autopsy.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Baseline characteristics of patients with GBAC</title><p>A total of 11 patients, including 2 rapid autopsy cases (GB-A1 and GB-A2) and 9 surgery cases (GB-S1 – 9), were enrolled in this study (<xref ref-type="table" rid="table1">Table 1</xref> and <xref ref-type="fig" rid="fig1">Figure 1A</xref>). There were 5 male and 6 female patients with a median age was 70 years (range, 59–75 years). Two patients had stage III and nine patients had IV disease at diagnosis. A total of 58 samples were analyzed, including 11 pairs of matched primary tumors and normal tissues, 6 concurrent BilIN, and 30 metastatic tumors. Among them, 15 samples obtained by rapid autopsy were fresh-frozen, and 43 samples obtained by surgery or biopsy were formalin-fixed paraffin-embedded (FFPE) (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1A</xref>). The median number of filtered somatic single nucleotide variants (SNVs) and small indels was 61 (range, 12–241). The number of metastatic tumors in each patient ranged from 1 to 11.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Clinical history of patients, mutational landscape, and study workflow.</title><p>(<bold>A</bold>) Clinical history of 11 patients is summarized in the swimmer plot. (<bold>B</bold>) The mutational landscape of 11 primary tumors (GB) is visualized and compared with the two previous studies on gallbladder adenocarcinoma (GBAC). (<bold>C</bold>) The process of constructing clonal evolution trajectories using multiple tumor samples is shown in the workflow. Ab, antibody; Abd, abdominal; Adj, adjuvant; BilIN, biliary intraepithelial neoplasia; CBD, common bile duct; CCRT, concurrent chemoradiotherapy; CNVs, copy number variations; COSMIC, Catalogue Of Somatic Mutations In Cancer; FL, 5-fluorouracil + leucovorin; FOLFIRI, 5-fluorouracil + leucovorin + irinotecan; GB, gallbladder; GP, gemcitabine + cisplatin; iFAM, infusional 5-fluorouracil + doxorubicin + mitomycin-C; LOH, loss of heterozygosity; mFOLFOX, modified 5-fluorouracil + leucovorin + oxaliplatin; MSKCC, Memorial Sloan Kettering Cancer Center; NE, not evaluable; SNVs, single nucleotide variants; WGD, whole genome doubling; XP, capecitabine + cisplatin; 5-FU, 5-fluorouracil.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78636-fig1-v3.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Inference of clonal structure by PyClone algorithm.</title><p>(<bold>A–K</bold>) The clonal population structure was statistically inferred for GB-A1 (<bold>A</bold>), GB-S1 (<bold>B</bold>), GB-S2 (<bold>C</bold>), GB-S3 (<bold>D</bold>), GB-A2 (<bold>E</bold>), GB-S4 (<bold>F</bold>), GB-S5 (<bold>G</bold>), GB-S6 (<bold>H</bold>), GB-S7 (<bold>I</bold>), GB-S8 (<bold>J</bold>), and GB-S9 (<bold>K</bold>) using PyClone. See <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref> to check the matching information for the PyClone clusters and the CITUP clones. BilIN, biliary intraepithelial neoplasia; GB, gallbladder; CBD, common bile duct; LN, lymph node.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78636-fig1-figsupp1-v3.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>BiIlN and primary gallbladder adenocarcinoma (GBAC) of the GB-S7 patient presumed to be derived from different origins.</title><p>(<bold>A</bold>) H&amp;E staining of BiIlN. (<bold>B</bold>) H&amp;E staining of GBAC. (<bold>C</bold>) Variant allele frequency of mutated genes in BilIN and primary GBAC. BilIN, biliary intraepithelial neoplasia; H&amp;E, hematoxylin and eosin.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78636-fig1-figsupp2-v3.tif"/></fig></fig-group><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Baseline characteristics of 11 patients with GBAC.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Patient ID<xref ref-type="table-fn" rid="table1fn1">*</xref></th><th align="left" valign="top">Sex</th><th align="left" valign="top">Age at diagnosis</th><th align="left" valign="top">ECOG PS at diagnosis</th><th align="left" valign="top">Stage at diagnosis</th><th align="left" valign="top">Differentiation</th></tr></thead><tbody><tr><td align="left" valign="top">GB-A1</td><td align="left" valign="top">F</td><td align="char" char="." valign="top">70</td><td align="char" char="." valign="top">1</td><td align="left" valign="top">IV</td><td align="left" valign="top">PD</td></tr><tr><td align="left" valign="top">GB-S1</td><td align="left" valign="top">F</td><td align="char" char="." valign="top">66</td><td align="char" char="." valign="top">1</td><td align="left" valign="top">IV</td><td align="left" valign="top">MD</td></tr><tr><td align="left" valign="top">GB-S2</td><td align="left" valign="top">F</td><td align="char" char="." valign="top">66</td><td align="char" char="." valign="top">1</td><td align="left" valign="top">IV</td><td align="left" valign="top">MD</td></tr><tr><td align="left" valign="top">GB-S3</td><td align="left" valign="top">F</td><td align="char" char="." valign="top">75</td><td align="char" char="." valign="top">1</td><td align="left" valign="top">III</td><td align="left" valign="top">MD</td></tr><tr><td align="left" valign="top">GB-A2</td><td align="left" valign="top">M</td><td align="char" char="." valign="top">61</td><td align="char" char="." valign="top">1</td><td align="left" valign="top">IV</td><td align="left" valign="top">MD</td></tr><tr><td align="left" valign="top">GB-S4</td><td align="left" valign="top">M</td><td align="char" char="." valign="top">72</td><td align="char" char="." valign="top">1</td><td align="left" valign="top">IV</td><td align="left" valign="top">MD</td></tr><tr><td align="left" valign="top">GB-S5</td><td align="left" valign="top">F</td><td align="char" char="." valign="top">70</td><td align="char" char="." valign="top">1</td><td align="left" valign="top">IV</td><td align="left" valign="top">PD</td></tr><tr><td align="left" valign="top">GB-S6</td><td align="left" valign="top">M</td><td align="char" char="." valign="top">70</td><td align="char" char="." valign="top">0</td><td align="left" valign="top">IV</td><td align="left" valign="top">MD</td></tr><tr><td align="left" valign="top">GB-S7</td><td align="left" valign="top">F</td><td align="char" char="." valign="top">74</td><td align="char" char="." valign="top">1</td><td align="left" valign="top">IV</td><td align="left" valign="top">PD</td></tr><tr><td align="left" valign="top">GB-S8</td><td align="left" valign="top">M</td><td align="char" char="." valign="top">67</td><td align="char" char="." valign="top">1</td><td align="left" valign="top">III</td><td align="left" valign="top">WD</td></tr><tr><td align="left" valign="top">GB-S9</td><td align="left" valign="top">M</td><td align="char" char="." valign="top">59</td><td align="char" char="." valign="top">0</td><td align="left" valign="top">IV</td><td align="left" valign="top">MD</td></tr></tbody></table><table-wrap-foot><fn id="table1fn1"><label>*</label><p>In patient ID, ‘A’ indicates autopsy cases whereas ‘S’ indicates surgery cases.</p></fn><fn><p>GBAC, gallbladder adenocarcinoma; ECOG PS, Eastern Cooperative Oncology Group performance status; M, male; F, female; PD, poorly differentiated; MD, moderately differentiated; WD, well-differentiated.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-2"><title>Mutational landscape and ploidy of primary tumors</title><p>The mutational landscape of the 11 primary tumors (GB) was analyzed and compared with previous literature (<xref ref-type="fig" rid="fig1">Figure 1B</xref>; <xref ref-type="bibr" rid="bib40">Narayan et al., 2019</xref>; <xref ref-type="bibr" rid="bib30">Li et al., 2014</xref>). The most frequently altered gene in the primary tumor was <italic>ERBB2</italic> and <italic>TP53</italic> (54.5%), followed by <italic>FBXW7</italic> (27.3%). Of the six <italic>ERBB2</italic> alterations, three were amplification and the other three were missense mutations classified as ‘pathogenic’ in the COSMIC (Catalogue Of Somatic Mutations In Cancer) v96 database. Among six <italic>TP53</italic> mutations found in six patients, five were accompanied by loss of heterozygosity (LOH).</p><p>Ploidy was analyzed in 15 tumors of six patients with purity &gt;0.4 because ploidy estimation was inaccurate when tumor purity is ≤0.4 (<xref ref-type="bibr" rid="bib13">Favero et al., 2015</xref>). In two patients (GB-S6 and GB-S9, 33.3%), whole genome doubling (WGD) was detected in both the primary and metastatic tumors (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). In GB-S5 patient, WGD was found in distant metastasis, but not in primary GBAC.</p></sec><sec id="s2-3"><title>Somatic mutations developed at the precancerous stage</title><p>Multi-regional distribution and longitudinal evolution of clones were analyzed using PyClone (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> and <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>; <xref ref-type="bibr" rid="bib46">Roth et al., 2014</xref>) and CITUP (<xref ref-type="bibr" rid="bib33">Malikic et al., 2015</xref>) and then visualized using MapScape and TimeScape (<xref ref-type="bibr" rid="bib47">Smith et al., 2017</xref>; <xref ref-type="fig" rid="fig1">Figure 1C</xref>). Among six patients having concurrent BilIN tissues, two patients were excluded from the further analysis. One patient had low tumor purity of BilIN (0.03) and the other patient had different truncal mutations of BilIN and primary GBAC, suggesting different origins of the two tumors (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>).</p><p>Most mutations in frequently altered genes in GBAC existed at the BilIN stage (10 of 13, 76.9%), but some of them were subclonal. In GB-A1 (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), <italic>TP53</italic> C100Y with LOH, <italic>KMT2C</italic> R909K<italic>, ERBB3</italic> G284R<italic>, ARID2</italic> F575fs with LOH, and <italic>CTNNB1</italic> S37F with LOH were observed clonally in BilIN. In GB-S1 (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), <italic>SAMD9</italic> E612K was clonal whereas <italic>FBXW7</italic> S18C<italic>, ARID1A</italic> S382N<italic>,</italic> and <italic>NF1</italic> R440X were subclonal. In GB-S2 (<xref ref-type="fig" rid="fig2">Figure 2C</xref>), considering the cellular prevalence of mutations, it is speculated that the mutations developed in the order of <italic>CDKN2A</italic> R58fs with LOH, <italic>TP53</italic> H82R with LOH, <italic>ERBB2</italic> V777L, and <italic>GNAS</italic> G306R during carcinogenesis. In GB-S3 (<xref ref-type="fig" rid="fig2">Figure 2D</xref>), <italic>ERBB3</italic> E332K was dominant in BilIN, while <italic>SMAD4</italic> 539_540del was not detected.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Spatial and temporal clonal evolution of four patients with gallbladder adenocarcinoma (GBAC) whose precancerous BilIN tissues were analyzed.</title><p>(<bold>A–D</bold>) The most probable phylogenetic trees and MapScape and TimeScape results are visualized for GB-A1 (<bold>A</bold>), GB-S1 (<bold>B</bold>), GB-S2 (<bold>C</bold>), and GB-S3 (<bold>D</bold>). In MapScape visualization (table), the numbers in the row indicate the time taken from diagnosis to tissue acquisition in months, and the columns indicate whether the tissue is a precancerous lesion, primary tumor, or metastatic lesion. Colors represent distinct clones and clonal prevalences per site were proportional to the corresponding-colored area of the cellular aggregate representation. In TimeScape visualization (schema), clonal prevalences (vertical axis) were plotted across time points (horizontal axis) for each clone (colors). Asterisks (*) in the clonal phylogenetic tree denote subclones that constituted &lt;5% in the primary tumor and expanded more than sevenfold in the metastatic tumor. Diamond symbol (◇) is used if the mutation in the figure is classified as 'pathogenic' in Catalogue Of Somatic Mutations In Cancer (COSMIC) v96. Notable events were marked with arrows. The time from diagnosis of GBAC to tissue acquisition was indicated under the sample name. Chemotherapy history was indicated in gray color, where '#' represents the number of chemotherapy cycles. BilIN, biliary intraepithelial neoplasia; CBD, common bile duct; CN, copy number; GB, gallbladder; GP, gemcitabine + cisplatin; LN, lymph node; LOH, loss of heterozygosity.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78636-fig2-v3.tif"/></fig></sec><sec id="s2-4"><title>Subclonal diversity and ‘selective sweep' phenomenon during the early stage of carcinogenesis</title><p>Branching evolution and subclonal diversity were commonly observed in the BilIN of the four patients (<xref ref-type="fig" rid="fig2">Figure 2</xref>). When compared with the concurrent primary tumors, one subclone commonly shrank in the primary tumors, while the other subclones that acquired additional mutations relatively expanded in the primary tumors, suggesting a selective sweep phenomenon (<xref ref-type="bibr" rid="bib35">Merlo et al., 2006</xref>). Selected subclones underwent linear and branching evolution, and thus subclonal diversity was maintained after the BilIN stage. In GB-A1 (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), clone A underwent branching evolution into B and G, and clone B linearly evolved into C and then D. Clone D, which acquired additional mutations, increased from 42.7% to 68.1% while clone G decreased from 55.7% to 2.8%. In GB-S1 (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), clone D that acquired <italic>KMT2D</italic> E338K increased from 0.1% to 28.1%, while clone G decreased from 51.4% to 0%. In GB-S2 (<xref ref-type="fig" rid="fig2">Figure 2C</xref>), clone D acquired <italic>ERBB2</italic> V777L, clone E acquired <italic>GNAS</italic> G306R, and clone G increased from 9.0%, 3.5%, and 0% to 45.5%, 22.3%, and 11.4%, respectively. In contrast, clone F decreased from 55.8% to 0.6%. In GB-S3 (<xref ref-type="fig" rid="fig2">Figure 2D</xref>), clone B that acquired <italic>SMAD4</italic> 539_540del increased from 0.1% to 65.6%, while clone D containing <italic>ERBB3</italic> E332K decreased from 81.1% to 0.6%.</p></sec><sec id="s2-5"><title>Evolutionary trajectories and expansion of subclones during regional and distant metastasis</title><p>Combined analysis of regional and distant metastatic tumors revealed branching and linear evolution in nine patients (81.8%) and linear evolution only in two patients (18.2%). Of the nine patients with branching and linear evolution, eight (88.9%) had a total of 11 subclones expanded at least sevenfold in the regional or distant metastasis stage (<xref ref-type="table" rid="table2">Table 2</xref>). In GB-A1 (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), clone E, which acquired <italic>JARID2</italic> (<xref ref-type="bibr" rid="bib5">Celik et al., 2018</xref>) K603Q with LOH, increased from 0.2% to 20.5% during common bile duct metastasis. In addition, clone F, which acquired <italic>SMAD4</italic> (<xref ref-type="bibr" rid="bib40">Narayan et al., 2019</xref>; <xref ref-type="bibr" rid="bib23">Jamal-Hanjani et al., 2017</xref>; <xref ref-type="bibr" rid="bib62">Yoon et al., 2021</xref>; <xref ref-type="bibr" rid="bib64">Zhao et al., 2018</xref>) L414fs with LOH, expanded from 0.4% to 49.8% during omentum 1 metastasis and to 27.0% during omentum 2 metastasis. In GB-S1 (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), clone B harboring <italic>SLIT3</italic> F843I mutation evolved into E by additionally acquiring <italic>ROBO1</italic> P1360Q mutation (<xref ref-type="bibr" rid="bib15">Gara et al., 2015</xref>). In GB-A2 (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), clone F, which acquired <italic>PRKCD</italic> (<xref ref-type="bibr" rid="bib18">Griner and Kazanietz, 2007</xref>; <xref ref-type="bibr" rid="bib63">Yoshida, 2007</xref>) I153L, expanded from 0.3% to 73.1% and 68.3% during metastasis to liver and mesentery, respectively. In addition, clone G acquired <italic>DICER1</italic> (<xref ref-type="bibr" rid="bib14">Foulkes et al., 2014</xref>) T519A and expanded from 2.8% to 39.9% and 61.5% during metastasis to the lung and chest wall, respectively. In the other five patients (<xref ref-type="fig" rid="fig2">Figures 2C</xref> and <xref ref-type="fig" rid="fig3">3B–E</xref>), mutations in <italic>FBXW2</italic> (<xref ref-type="bibr" rid="bib58">Xu et al., 2017</xref>), <italic>KIAA0100</italic> (<xref ref-type="bibr" rid="bib16">Gara et al., 2018</xref>), <italic>CSMD2</italic> (<xref ref-type="bibr" rid="bib16">Gara et al., 2018</xref>), and <italic>OSCP1</italic> (<xref ref-type="bibr" rid="bib60">Yi et al., 2017</xref>) genes were observed.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Spatial and temporal clonal evolution of additional seven patients with gallbladder adenocarcinoma (GBAC).</title><p>(<bold>A–G</bold>) The most probable phylogenetic trees and MapScape and TimeScape results are visualized for GB-A2 (<bold>A</bold>), GB-S4 (<bold>B</bold>), GB-S5 (<bold>C</bold>), GB-S6 (<bold>D</bold>), GB-S7 (<bold>E</bold>), GB-S8 (<bold>F</bold>), and GB-S9 (<bold>G</bold>). In MapScape visualization (table), the numbers in the row indicate the time taken from diagnosis to tissue acquisition in months, and the columns indicate whether the tissue is a precancerous lesion, primary tumor, or metastatic lesion. Colors represent distinct clones and clonal prevalences per site were proportional to the corresponding-colored area of the cellular aggregate representation. In TimeScape visualization (schema), clonal prevalences (vertical axis) were plotted across time points (horizontal axis) for each clone (colors). Asterisks (*) in the clonal phylogenetic tree denote subclones that constituted &lt;5% in the primary tumor and expanded more than sevenfold in the metastatic tumor. Diamond symbol (◇) is used if the mutation in the figure is classified as 'pathogenic' in Catalogue Of Somatic Mutations In Cancer (COSMIC) v96. Notable events were marked with arrows. The time from diagnosis of GBAC to tissue acquisition was indicated under the sample name. Chemotherapy history was indicated in gray color, where '#' represents the number of chemotherapy cycles. Adj, adjuvant; BilIN, biliary intraepithelial neoplasia; CN, copy number; FL, 5-fluorouracil + leucovorin; GB, gallbladder; GP, gemcitabine + cisplatin; LN, lymph node; LOH, loss of heterozygosity; WGD, whole genome doubling.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78636-fig3-v3.tif"/></fig><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>List of subclones expanding during metastasis.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Patient ID</th><th align="left" valign="top">Subclone</th><th align="left" valign="top">No. of mutations</th><th align="left" valign="top">Putative driver mutations</th><th align="left" valign="top">Clonal prevalence in primary tumor</th><th align="left" valign="top">Clonal prevalence in metastasis</th><th align="left" valign="top">Metastatic organ</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="3">GB-A1</td><td align="left" valign="top">E</td><td align="char" char="." valign="top">121</td><td align="left" valign="top"><italic>JARID2</italic> p.K603Q (LOH)</td><td align="char" char="." valign="top">0.2%</td><td align="char" char="." valign="top">20.5%</td><td align="left" valign="top">CBD</td></tr><tr><td align="left" valign="top" rowspan="2">F</td><td align="char" char="." valign="top" rowspan="2">54</td><td align="left" valign="top" rowspan="2"><italic>SMAD4</italic> p.L414fs (LOH)</td><td align="char" char="." valign="top" rowspan="2">0.4%</td><td align="char" char="." valign="top">49.8%</td><td align="left" valign="top">Omentum 1</td></tr><tr><td align="char" char="." valign="top">27.0%</td><td align="left" valign="top">Omentum 2</td></tr><tr><td align="left" valign="top">GB-S1</td><td align="left" valign="top">E</td><td align="char" char="." valign="top">6</td><td align="left" valign="top"><italic>ROBO1</italic> p.P1360Q</td><td align="char" char="." valign="top">0.0%</td><td align="char" char="." valign="top">59.2%</td><td align="left" valign="top">Distant LN</td></tr><tr><td align="left" valign="top">GB-S2</td><td align="left" valign="top">H</td><td align="char" char="." valign="top">6</td><td align="left" valign="top">–</td><td align="char" char="." valign="top">1.2%</td><td align="char" char="." valign="top">28.1%</td><td align="left" valign="top">Regional LN</td></tr><tr><td align="left" valign="top" rowspan="4">GB-A2</td><td align="left" valign="top" rowspan="2">F</td><td align="char" char="." valign="top" rowspan="2">14</td><td align="left" valign="top" rowspan="2"><italic>PRKCD</italic> p.I153L</td><td align="char" char="." valign="top" rowspan="2">0.3%</td><td align="char" char="." valign="top">73.1%</td><td align="left" valign="top">Liver</td></tr><tr><td align="char" char="." valign="top">68.3%</td><td align="left" valign="top">Mesentery</td></tr><tr><td align="left" valign="top" rowspan="2">G</td><td align="char" char="." valign="top" rowspan="2">3</td><td align="left" valign="top" rowspan="2"><italic>DICER1</italic> p.T519A</td><td align="char" char="." valign="top" rowspan="2">2.8%</td><td align="char" char="." valign="top">39.9%</td><td align="left" valign="top">Lung</td></tr><tr><td align="char" char="." valign="top">61.5%</td><td align="left" valign="top">Chest wall</td></tr><tr><td align="left" valign="top" rowspan="2">GB-S4</td><td align="left" valign="top">F</td><td align="char" char="." valign="top">32</td><td align="left" valign="top"><italic>FBXW2</italic> p.W450C</td><td align="char" char="." valign="top">0.0%</td><td align="char" char="." valign="top">34.1%</td><td align="left" valign="top">Colon wall</td></tr><tr><td align="left" valign="top">H</td><td align="char" char="." valign="top">36</td><td align="left" valign="top">–</td><td align="char" char="." valign="top">0.0%</td><td align="char" char="." valign="top">34.9%</td><td align="left" valign="top">Distant LN</td></tr><tr><td align="left" valign="top" rowspan="2">GB-S5</td><td align="left" valign="top" rowspan="2">B</td><td align="char" char="." valign="top" rowspan="2">28</td><td align="left" valign="top"><italic>KIAA0100</italic> p.F5S</td><td align="char" char="." valign="top" rowspan="2">1.2%</td><td align="char" char="." valign="top" rowspan="2">54.4%</td><td align="left" valign="top" rowspan="2">Liver</td></tr><tr><td align="left" valign="top"><italic>CSMD2</italic> p.E411K</td></tr><tr><td align="left" valign="top">GB-S6</td><td align="left" valign="top">B</td><td align="char" char="." valign="top">7</td><td align="left" valign="top"><italic>OSCP1</italic> p.R351X</td><td align="char" char="." valign="top">1.1%</td><td align="char" char="." valign="top">60.2%</td><td align="left" valign="top">Lung</td></tr><tr><td align="left" valign="top">GB-S7</td><td align="left" valign="top">C</td><td align="char" char="." valign="top">5</td><td align="left" valign="top">–</td><td align="char" char="." valign="top">3.3%</td><td align="char" char="." valign="top">24.7%</td><td align="left" valign="top">Regional LN</td></tr></tbody></table><table-wrap-foot><fn><p>Putative driver mutations are indicated, and a full list of mutated genes is specified in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>.</p></fn><fn><p>GB, gallbladder; LN, lymph node; CBD, common bile duct.</p></fn></table-wrap-foot></table-wrap><p>In GB-S8 and GB-S9, only linear evolution was identified (<xref ref-type="fig" rid="fig3">Figure 3F and G</xref>). In GB-S9, amplification of cell cycle-related oncogenes <italic>CDKN1B</italic> and <italic>CCNE1</italic> was uniformly observed from primary GBAC to regional and distant metastatic tumors.</p></sec><sec id="s2-6"><title>Polyclonal metastasis and intermetastatic heterogeneity</title><p>The metastatic lesions were uniformly polyclonal. In GB-A1, GB-A2, and GB-S4, which contained two or more distant metastatic lesions, the clonal composition of tissues obtained from the same or adjacent organs showed a similar tendency, while the clonal composition of anatomically distant organs was distinct from each other. In GB-A1 (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), abdominal wall 1–4 did not contain clone C, and liver 1–3 did not contain clone F. In addition, omentum 1–2 had a high prevalence of clone F of over 27.0%. In GB-A2 (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), as opposed to clone G, which was more prevalent in lung and chest wall lesions, clone F was more prevalent in liver and mesentery lesions. In clinical information of the GB-A2 patient, chest wall and mesentery metastases developed later than lung and liver metastases. In GB-S4 (<xref ref-type="fig" rid="fig3">Figure 3B</xref>), proportions of clones G and H were specifically high in distant LN and colon wall metastasis, respectively.</p></sec><sec id="s2-7"><title>Mutational signatures during clonal evolution</title><p>We identified six mutational signatures (cosine similarity &gt;0.9): signatures 1 (age), 3 (DNA double-strand break-repair), 7 (ultraviolet), 13 (APOBEC), 22 (aristolochic acid), and 24 (aflatoxin). Then, our results were compared with those of the Memorial Sloan Kettering Cancer Center (MSKCC) and Shanghai datasets (<xref ref-type="bibr" rid="bib40">Narayan et al., 2019</xref>; <xref ref-type="bibr" rid="bib30">Li et al., 2014</xref>). While MSKCC and Shanghai datasets consist merely of primary tumors, our dataset includes precancerous and metastatic lesions. Signatures 1, 3, and 13 were commonly dominant in all three datasets, while signatures 22 and 24 were exclusive in our dataset (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). In our dataset, the limited number of SNVs and small indels per sample (median 61, range 12–241) made it difficult to compare among individual tumors (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Therefore, we classified the mutations according to the timing of development during clonal evolution (<xref ref-type="fig" rid="fig4">Figure 4B</xref>): (1) early carcinogenesis (i.e<italic>.,</italic> clone A in <xref ref-type="fig" rid="fig2">Figures 2</xref> and <xref ref-type="fig" rid="fig3">3</xref>), (2) late carcinogenesis (i.e<italic>.,</italic> subclones which were not categorized in early carcinogenesis or metastasis), and (3) metastasis (i.e<italic>.,</italic> subclones expanding during metastasis [<xref ref-type="table" rid="table2">Table 2</xref>]). At the metastasis phase, signatures 1 and 13 decreased while signatures 22 and 24 increased compared with early and late carcinogenesis. Then, the same analysis was performed according to the type of sample (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>): (1) BilIN, (2) GB, (3) regional LN metastasis, and (4) distant metastasis. This mutational signature analysis was conducted using the published tool Mutalisk (<xref ref-type="bibr" rid="bib28">Lee et al., 2018</xref>) and then validated with two additional tools, Signal (<xref ref-type="bibr" rid="bib11">Degasperi et al., 2020</xref>) and MuSiCa (<xref ref-type="bibr" rid="bib12">Díaz-Gay et al., 2018</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1B</xref> and <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Mutational signature analysis.</title><p>(<bold>A–B</bold>) The 100% stacked bar plots compare the proportions of known COSMIC Mutational Signatures v2 within our dataset and two public (MSKCC and Shanhai) datasets (<bold>A</bold>), and each category split according to the timing of development during clonal evolution (<bold>B</bold>). The total number of mutations (N) and cosine similarity (CS) values of each category were noted. BilIN, biliary intraepithelial neoplasia; COSMIC, Catalogue Of Somatic Mutations In Cancer; GB, gallbladder; LN, lymph node; MSKCC, Memorial Sloan Kettering Cancer Center.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78636-fig4-v3.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Mutational signatures within each sample from 11 gallbladder adenocarcinoma (GBAC) patients.</title><p>The 100% stacked bar plots comparing the proportions of known COSMIC Mutational Signatures v2 within each sample from 11 GBAC patients. BilIN, biliary intraepithelial neoplasia; CBD, common bile duct; COSMIC, Catalogue Of Somatic Mutations in Cancer; GB, gallbladder; LN, lymph node.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78636-fig4-figsupp1-v3.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Mutational signatures within each category split according to the type of sample.</title><p>The 100% stacked bar plots comparing the proportions of known COSMIC Mutational Signatures v2 within each category split according to the type of sample. The total number of mutations (N) and cosine similarity (CS) values of each category were noted. BilIN, biliary intraepithelial neoplasia; COSMIC, Catalogue Of Somatic Mutations In Cancer; GB, gallbladder; LN, lymph node.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78636-fig4-figsupp2-v3.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Mutational signature analysis validated by two additional tools, Signal and MuSiCa.</title><p>The 100% stacked bar plots comparing the proportions of known COSMIC Mutational Signatures v2 within each category split according to the timing of development during clonal evolution. The total number of mutations (N) and cosine similarity (CS) values of each category were noted. COSMIC, Catalogue Of Somatic Mutations in Cancer.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78636-fig4-figsupp3-v3.tif"/></fig></fig-group></sec><sec id="s2-8"><title><italic>ERBB2</italic> amplification during clonal evolution</title><p>In GB-A1, <italic>ERBB2</italic> copy number gain might have initiated from the precancerous stage and further progressed during the malignant transformation of BilIN. <italic>ERBB2</italic> copy number (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref>) was 3 and 9 in concurrent BillN and primary tumors, respectively. The increased copy number of <italic>ERBB2</italic> was maintained after distant metastasis (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). <italic>HER2</italic> (=<italic>ERBB2</italic>) silver in situ hybridization (SISH) (<xref ref-type="fig" rid="fig5">Figure 5C and D</xref>) was conducted and <italic>ERBB2</italic> copy number per cell ranged from 1 to 5 in BilIN, and from 2 to 14 in primary GBAC. <italic>ERBB2</italic>/CEP17 ratio was 2.48 and 6.00 in BilIN and primary GBAC, respectively (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). In addition, <italic>HER2</italic> immunohistochemistry (IHC) (<xref ref-type="fig" rid="fig5">Figure 5F and G</xref>) was carried out to evaluate whether the <italic>ERBB2</italic> amplification was correlated to <italic>HER2</italic> protein expression levels on the membrane of tumor cells. The <italic>HER2</italic> IHC results were 2+/3 in the BillN and 3+/3 in primary GBAC. In GB-S6 and GB-S7 (<xref ref-type="fig" rid="fig3">Figure 3D and E</xref>), <italic>ERBB2</italic> amplification was uniformly identified from primary tumors to metastatic tumors.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title><italic>ERBB2</italic> copy number variation during neoplastic transformation of BilIN in GB-A1.</title><p>(<bold>A–G</bold>) <italic>ERBB2</italic> gene amplification (<bold>A and B</bold>), <italic>HER2</italic> SISH (<bold>C and D</bold>), and <italic>HER2</italic> IHC (<bold>F and G</bold>) were compared between BilIN (<bold>A, C</bold>) and (<bold>F</bold>) and primary GBAC (<bold>B</bold>), (<bold>D</bold>), and (<bold>G</bold>) samples and the mean <italic>ERBB2</italic>/CEP17 ratio of BilIN and GB-A1 samples were compared by using the Wilcoxon rank-sum test (<bold>E</bold>). BilIN, biliary intraepithelial neoplasia; GBAC, gallbladder adenocarcinoma; IHC, immunohistochemistry; SISH, silver in situ hybridization.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78636-fig5-v3.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>To the best of our knowledge, this is the first study to investigate clonal evolution from precancerous lesions to metastatic tumors in patients with GBAC. In this study, evolutionary trajectories of GBAC were inferred using multi-regional and longitudinal whole-exome sequencing (WES) data from precancerous lesions to primary and metastatic tumors. Based on these results, we derived comprehensive models of carcinogenesis and metastasis in GBAC.</p><p>In our analysis of carcinogenesis, we discovered three common themes. First, most mutations in frequently altered genes in primary GBAC are detected in concurrent BilIN (10 of 13, 76.9%), but a substantial proportion was subclonal. Second, branching evolution and subclonal diversity are commonly observed at the BilIN stage. Third, one subclone in BilIN commonly shrinks in the primary tumors, while the other subclones undergo linear and branching evolution, maintaining subclonal diversity after the BilIN stage. A previous study in colorectal cancer by Vogelstein and colleagues demonstrated a stepwise carcinogenesis model from the precancerous lesion, adenoma, to invasive carcinoma by the accumulation of mutations, called the adenoma-carcinoma sequence (<xref ref-type="bibr" rid="bib54">Vogelstein et al., 1988</xref>). In addition, recent studies on esophageal squamous cell carcinoma have reported that not only dysplasia but also histologically normal epithelia frequently harbor cancer-driving mutations (<xref ref-type="bibr" rid="bib7">Chen et al., 2017</xref>; <xref ref-type="bibr" rid="bib61">Yokoyama et al., 2019</xref>).</p><p>A recent study on GBAC (<xref ref-type="bibr" rid="bib32">Lin et al., 2021</xref>) reported that <italic>CTNNB1</italic> mutation was frequently observed (5 out of 11) when BilIN and primary GBAC coexist. In addition, <italic>ERBB2</italic> alteration was found in 36.4%. In our study, <italic>CTNNB1</italic> S37F with LOH was observed in one (GB-A1) of four patients and 54.5% of patients had an <italic>ERBB2</italic> alteration. On the other hand, two previous studies on GBAC (<xref ref-type="bibr" rid="bib40">Narayan et al., 2019</xref>; <xref ref-type="bibr" rid="bib30">Li et al., 2014</xref>) reported the prevalence of <italic>ERBB2</italic> alteration as low as 7.9% and 9.4%, respectively. Race or lifestyle differences might have contributed to the difference.</p><p>In the analysis of metastasis, the following three phenomena are observed. First, subclonal expansion is frequent (8 of 11 patients, 72.7%) and some subclones expand substantially in metastatic tumors, leading to increased subclonal diversity. Previous studies suggest that subclonal diversity increases through branching evolution during progression and metastasis (<xref ref-type="bibr" rid="bib48">Turajlic and Swanton, 2016</xref>; <xref ref-type="bibr" rid="bib21">Hong et al., 2015</xref>; <xref ref-type="bibr" rid="bib59">Yachida et al., 2010</xref>; <xref ref-type="bibr" rid="bib36">Minussi et al., 2021</xref>). Second, metastases are polyclonal but metastatic lesions in one organ or adjacent organs show similar clonal compositions. Previously, it was thought that metastasis is initiated by the migration of a single cell to another organ (<xref ref-type="bibr" rid="bib42">Nowell, 1976</xref>). However, recent data suggest that polyclonal seeding occurs due to the migration of a cluster of cancer cells (<xref ref-type="bibr" rid="bib50">Turajlic et al., 2019</xref>; <xref ref-type="bibr" rid="bib8">Cheung and Ewald, 2016</xref>; <xref ref-type="bibr" rid="bib51">Ullah et al., 2018</xref>; <xref ref-type="bibr" rid="bib56">Wei et al., 2017</xref>). Third, we found the possibility of metastasis to metastasis spread. In recent studies on prostate and breast cancers, metastasis-to-metastasis spread was frequent (<xref ref-type="bibr" rid="bib51">Ullah et al., 2018</xref>; <xref ref-type="bibr" rid="bib19">Gundem et al., 2015</xref>). Our study found the possibility of metastasis-to-metastasis spread in GB-A2 (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Although intratumoral heterogeneity of primary GBAC may make it difficult to draw a strong conclusion, our data may support the possibility of metastasis-to-metastasis spread.</p><p>Of the 11 expanded subclones at the metastasis stage, we described putative driver mutations in eight subclones based on the previous literature (<xref ref-type="table" rid="table2">Table 2</xref>). For example, <italic>SMAD4</italic> mutations expanded during metastasis in GB-A1 and GB-S3 (<xref ref-type="fig" rid="fig2">Figure 2A and D</xref>) and have been associated with distant metastasis and poor prognosis in various cancers, including GBAC (<xref ref-type="bibr" rid="bib40">Narayan et al., 2019</xref>; <xref ref-type="bibr" rid="bib23">Jamal-Hanjani et al., 2017</xref>; <xref ref-type="bibr" rid="bib62">Yoon et al., 2021</xref>; <xref ref-type="bibr" rid="bib64">Zhao et al., 2018</xref>). In GB-S1 (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), clone B containing <italic>SLIT3</italic> F843I evolves into E during metastasis by acquiring <italic>ROBO1</italic> P1360Q. The SLIT/ROBO pathway suppresses tumor progression by regulating invasion, migration, and apoptosis (<xref ref-type="bibr" rid="bib15">Gara et al., 2015</xref>). In GB-A2 (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), <italic>DICER1</italic> T519A is found in lung and chest wall metastases. The <italic>DICER1</italic> gene is associated with pleuropulmonary blastoma in children (<xref ref-type="bibr" rid="bib14">Foulkes et al., 2014</xref>). In GB-S5 (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), <italic>KIAA0100</italic> F5S and <italic>CSMD2</italic> E411K are found during metastasis. <italic>KIAA0100</italic> and <italic>CSMD2</italic> are frequently mutated during metastasis in adrenocortical carcinoma (<xref ref-type="bibr" rid="bib16">Gara et al., 2018</xref>).</p><p>In mutational signature analysis, considering the evolutionary trajectories in cancers, we suggest that the timing of development during clonal evolution (<xref ref-type="fig" rid="fig4">Figure 4B</xref>) is better classification criterion than the type of sample (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). Our data indicate that the importance of signatures 1 and 13 decreased during metastasis while the roles of signatures 22 and 24 were relatively highlighted. Aristolochic acid is an ingredient of oriental herbal medicine (<xref ref-type="bibr" rid="bib10">Debelle et al., 2008</xref>; <xref ref-type="bibr" rid="bib20">Hoang et al., 2013</xref>). In addition, aflatoxin is known to be contained in soybean paste and soy sauce (<xref ref-type="bibr" rid="bib44">Ok et al., 2007</xref>). Taken together, the two carcinogens might have little impact on the early stage of cancer development, but their impacts might be highlighted in overt cancer cells.</p><p>In this cancer precision medicine era, targeted sequencing data of a single specimen are not enough to determine whether the detected mutations are clonal or subclonal. This proof-of-concept study may enable us to deeply understand the clonal evolution in GBAC. Moreover, we found that some of the mutations were clonal while a substantial proportion was subclonal, which is usually not an effective druggable target. For example, if a drug targeting <italic>ERBB2</italic> p.V777L, a pathogenic mutation, is administered to GB-S2 patient (<xref ref-type="fig" rid="fig2">Figure 2C</xref>), the therapeutic effect will be limited in subclones without the <italic>ERBB2</italic> p.V777L mutation, especially from regional metastasis. Therefore, we believe that our study highlights the importance of precise genomic analysis of multi-regional and longitudinal samples in individual cancer patients. However, one caveat is that we cannot easily apply this to real-world patients because multi-regional and longitudinal tumor biopsies may not be feasible in most patients unless they underwent surgery and repeated biopsies. Recent studies using circulating tumor DNA have shown the possibility of easily detecting mutations involved in cancer development and progression (<xref ref-type="bibr" rid="bib22">Ignatiadis et al., 2021</xref>). By detecting clonal mutations from the carcinogenesis stage in healthy individuals, we can diagnose GBAC at an early stage. In addition, by detecting subclonal mutations in patients with GBAC, we can monitor the expanding subclones during follow-up, which enables us to detect cancer progression earlier.</p><p>This study has several limitations. First, it is not possible to obtain samples through frequent biopsies whenever desired. Thus, tumor samples were not acquired according to their developmental sequence. Second, due to intratumoral heterogeneity, the clonal composition of a small piece of the tumor may not reflect that of the entire lesion (<xref ref-type="bibr" rid="bib34">Marusyk et al., 2012</xref>). Third, as the number of analyzed samples was different among patients, an accessibility bias was inevitable – the more samples the patient has, the more clones we can identify.</p><p>In conclusion, subclonal diversity developed early in precancerous lesions and clonal selection was a common event during malignant transformation in GBAC. However, cancer clones continued to evolve in metastatic tumors and thus maintained subclonal diversity. Our novel approach may help us to understand the GBAC of individual patients and to move forward to precision medicine that enables early detection of carcinogenesis and metastasis, and effective targeted therapy in these patients.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Patients and tumor samples</title><p>Patients were eligible for this study if they were diagnosed with GBAC and received surgery between 2013 and 2018 at Seoul National University Bundang Hospital (SNUBH), Seongnam, Korea. Of the 272 patients who underwent surgery, 9 patients who were able to obtain ≥3 types of tissue from among BilIN, GBAC, regional LN metastasis, and distant metastasis and died at the time of analysis were enrolled in the study. In addition, two patients who donated their bodies for rapid autopsy were included in the study. Our board-certified pathologists (Prof. Soomin Ahn and Hee Young Na) identified and dissected BilIN and GBAC lesions from tissue slides. Patients’ clinical information was obtained through retrospective medical record reviews. This study was approved by the Institutional Review Board (IRB) of SNUBH (IRB No. B-1902/522-303). Informed consent was waived because of the retrospective and anonymous nature of the study.</p></sec><sec id="s4-2"><title>WES of GBAC</title><p>DNA was extracted from fresh-frozen or FFPE tissues. Library preparation and exome capture was carried out using Agilent SureSelect<sup>XT</sup> Human All Exon V6 (Santa Clara, CA, USA). WES was conducted with a paired-end, 100 bp using Illumina NovaSeq 6000 (San Diego, CA, USA). The depth of coverage of tumors and normal control samples were at least 300× and 200×, respectively.</p></sec><sec id="s4-3"><title>Analysis of WES data</title><p>WES data of GBAC and matched normal samples were analyzed using the Genomon2 pipeline (Institute of Medical Science, University of Tokyo, Tokyo, Japan; <ext-link ext-link-type="uri" xlink:href="https://genomon.readthedocs.io/ja/latest/">https://genomon.readthedocs.io/ja/latest/</ext-link>, accessed on February 1, 2022). In brief, sequencing reads from adapter-trimmed.fastq files were aligned to the human reference genome GRCh37 (hg19) without the ‘chr’ prefix using Burrows-Wheeler Aligner version 0.7.12, with default settings. SNVs and small indels were called by eliminating polymorphisms and sequencing errors and filtered by pre-specified criteria used in previous literature analyzed with the Genomon2 pipeline (<xref ref-type="bibr" rid="bib61">Yokoyama et al., 2019</xref>; <xref ref-type="bibr" rid="bib24">Kakiuchi et al., 2020</xref>; <xref ref-type="bibr" rid="bib43">Ochi et al., 2021</xref>): (a) only exonic or splicing sites were included; (b) synonymous SNVs, unknown variants, or those without proper annotation were excluded; (c) polymorphisms in dbSNP 131 were excluded; (d) p-values &lt;0.01 from Fisher’s exact test were included; (e) simple repeat sequences were excluded; (f) strand ratio between positive-strand and negative-strand should not be 0 or 1 in tumor samples; (g) the number of variant reads should exceed 4 in tumor samples. For each patient, filtered variant lists of tumor samples were merged. Then, the merged list of target variants was manually called in each.bam file using bam-readcount version 0.8.0 (<ext-link ext-link-type="uri" xlink:href="https://github.com/genome/bam-readcount">https://github.com/genome/bam-readcount</ext-link>; <xref ref-type="bibr" rid="bib25">Khanna et al., 2022a</xref>; <xref ref-type="bibr" rid="bib26">Khanna et al., 2022b</xref>, accessed on February 1, 2022) with Phred score and mapping quality of more than 30 and 60, respectively.</p><p>For samples with tumor purity &gt;0.4, the ploidy of tumor cells was estimated using Sequenza version 3.0.0 to identify WGD (<xref ref-type="bibr" rid="bib13">Favero et al., 2015</xref>). Copy number variations were analyzed using the Control-FREEC version 11.5 (<xref ref-type="bibr" rid="bib2">Boeva et al., 2012</xref>). Gene amplification was defined as a copy number ≥6 (<xref ref-type="bibr" rid="bib57">Wolff et al., 2018</xref>). In brief, the aligned.bam files were converted to.pileup.gz format using SAMtools version 1.9 (<xref ref-type="bibr" rid="bib29">Li, 2011</xref>). The .pileup.gz files of data from GBAC and matched normal samples were analyzed using Control-FREEC with default settings. These datasets were then used to statistically infer clonal population structure using PyClone version 0.13.0 with the ‘pyclone_beta_binomial’ model (<xref ref-type="bibr" rid="bib46">Roth et al., 2014</xref>). Clonal phylogeny was inferred by CITUP version 0.1.0 (<xref ref-type="bibr" rid="bib33">Malikic et al., 2015</xref>) using cellular prevalence values of each cluster which were generated by PyClone. CITUP uses information from multiple samples and can infer clonal populations and their frequencies while satisfying phylogenetic constraints. To ensure accurate tree construction, clusters containing only one mutation were excluded from the input to CITUP if the mutation’s role is unclear from previous literature. This filter removed 42 mutations from a total of 1577 mutations, representing less than 2.7% of all clustered mutations. In addition, in GB-A2, clusters which limited to only one organ were excluded from the analysis because the calculation for the phylogenetic tree using CITUP took more than 1 month when the number of clusters was ≥14. Analyzed results were visualized using MapScape for multi-regional specimens and TimeScape for longitudinal or putative longitudinal datasets, as appropriate (<xref ref-type="bibr" rid="bib47">Smith et al., 2017</xref>). In all analysis steps, the data were adjusted for the tumor purity values of each tumor.</p><p>Mutational signature analysis was conducted using Mutalisk (<xref ref-type="bibr" rid="bib28">Lee et al., 2018</xref>) and validated with Signal (<xref ref-type="bibr" rid="bib11">Degasperi et al., 2020</xref>) and MuSiCa (<xref ref-type="bibr" rid="bib12">Díaz-Gay et al., 2018</xref>). The COSMIC Mutational Signatures v2 (<xref ref-type="bibr" rid="bib1">Alexandrov et al., 2013</xref>) was used as a reference. To compare with the other GBAC cohorts, we additionally analyzed two public datasets of GBAC from the MSKCC and the Shanghai group (<xref ref-type="bibr" rid="bib40">Narayan et al., 2019</xref>; <xref ref-type="bibr" rid="bib30">Li et al., 2014</xref>), which could be downloaded from the cBioPortal (<ext-link ext-link-type="uri" xlink:href="https://www.cbioportal.org/">https://www.cbioportal.org/</ext-link>, accessed on February 1, 2022; <xref ref-type="bibr" rid="bib6">Cerami et al., 2012</xref>).</p></sec><sec id="s4-4"><title><italic>HER2</italic> IHC and SISH</title><p>The histologic sections from individual FFPE tissues were deparaffinized and dehydrated. IHC and SISH analysis of <italic>HER2</italic>-positive cells was conducted by the board-certified pathologist using PATHWAY anti-<italic>HER2</italic>/neu antibody (4B5; rabbit monoclonal; Ventana Medical Systems, Tucson, AZ, USA) and a staining device (BenchMark XT, Ventana Medical Systems, Tuscon, AZ, USA), respectively, as previously described (<xref ref-type="bibr" rid="bib27">Koh et al., 2019</xref>). Signals from 20 tumor cells were counted and a <italic>HER2</italic>/CEP17 ratio ≥2.0 was defined as <italic>HER2</italic> amplification (<xref ref-type="bibr" rid="bib57">Wolff et al., 2018</xref>). Wilcoxon rank-sum test is used to compare the mean <italic>HER2</italic>/CEP17 ratio of BilIN versus primary tumor.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Software, Formal analysis, Validation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Resources, Data curation, Formal analysis, Validation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Resources, Formal analysis, Supervision, Validation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Resources, Data curation, Software, Formal analysis, Supervision, Funding acquisition, Validation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Formal analysis, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Formal analysis, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Formal analysis, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Resources, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Resources, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Resources, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Resources, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Resources, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Resources, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con16"><p>Resources, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con17"><p>Resources, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con18"><p>Resources, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con19"><p>Resources, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con20"><p>Resources, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con21"><p>Resources, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: This study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of Seoul National University Bundang Hospital (Number: B-1902/522-303). Informed consent was waived because of the retrospective and anonymous nature of the study.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Tables.</title><p>(A) Baseline characteristics of samples are summarized. (B) Mutational signatures of our dataset are analyzed by three different tools, Mutalisk, Signal, and MuSiCa.</p></caption><media xlink:href="elife-78636-supp1-v3.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Detected somatic alternations in 11 patients with gallbladder adenocarcinoma (GBAC).</title><p>Full list of mutations called in our cohort.</p></caption><media xlink:href="elife-78636-supp2-v3.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-78636-mdarchecklist1-v3.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The raw sequence data underlying this manuscript are available as fastq files at the NCBI SRA database under the BioProject number PRJNA821382.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>M</given-names></name><name><surname>Na</surname><given-names>HY</given-names></name><name><surname>Ahn</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>J-W</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Ahn</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Youk</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>HT</given-names></name><name><surname>Kim</surname><given-names>K-J</given-names></name><name><surname>Suh</surname><given-names>KJ</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Lee</surname><given-names>KW</given-names></name><name><surname>Yoon</surname><given-names>YS</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Ho-Seong</surname><given-names>ZH</given-names></name><name><surname>Jin-Haeng</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Whole-exome sequencing of gallbladder carcinoma</data-title><source>NCBI Sequence Read Archive</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/sra/PRJNA821382">PRJNA821382</pub-id></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset2"><person-group person-group-type="author"><name><surname>Narayan</surname><given-names>RR</given-names></name></person-group><year iso-8601-date="2018">2018</year><data-title>Gallbladder Cancer (MSK, Cancer 2018)</data-title><source>cBioPortal</source><pub-id pub-id-type="accession" xlink:href="https://www.cbioportal.org/study?id=gbc_msk_2018">Gallbladder-Cancer-(MSK)</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset3"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><data-title>Gallbladder Carcinoma (Shanghai, Nat Genet 2014)</data-title><source>cBioPortal</source><pub-id pub-id-type="accession" xlink:href="https://www.cbioportal.org/study?id=gbc_shanghai_2014">Gallbladder-Carcinoma-(Shanghai)</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>This study was supported by a grant from Seoul National University Bundang Hospital Research Fund (No. 16-2021-001) and the Small Grant for Exploratory Research (SGER) program (NRF-2018R1D1A1A02086240) of the National Research Foundation (NRF), Korea. The authors would like to express the deepest respect to the two patients who donated their bodies for this study after death.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandrov</surname><given-names>LB</given-names></name><name><surname>Nik-Zainal</surname><given-names>S</given-names></name><name><surname>Wedge</surname><given-names>DC</given-names></name><name><surname>Aparicio</surname><given-names>SAJR</given-names></name><name><surname>Behjati</surname><given-names>S</given-names></name><name><surname>Biankin</surname><given-names>AV</given-names></name><name><surname>Bignell</surname><given-names>GR</given-names></name><name><surname>Bolli</surname><given-names>N</given-names></name><name><surname>Borg</surname><given-names>A</given-names></name><name><surname>Børresen-Dale</surname><given-names>A-L</given-names></name><name><surname>Boyault</surname><given-names>S</given-names></name><name><surname>Burkhardt</surname><given-names>B</given-names></name><name><surname>Butler</surname><given-names>AP</given-names></name><name><surname>Caldas</surname><given-names>C</given-names></name><name><surname>Davies</surname><given-names>HR</given-names></name><name><surname>Desmedt</surname><given-names>C</given-names></name><name><surname>Eils</surname><given-names>R</given-names></name><name><surname>Eyfjörd</surname><given-names>JE</given-names></name><name><surname>Foekens</surname><given-names>JA</given-names></name><name><surname>Greaves</surname><given-names>M</given-names></name><name><surname>Hosoda</surname><given-names>F</given-names></name><name><surname>Hutter</surname><given-names>B</given-names></name><name><surname>Ilicic</surname><given-names>T</given-names></name><name><surname>Imbeaud</surname><given-names>S</given-names></name><name><surname>Imielinski</surname><given-names>M</given-names></name><name><surname>Jäger</surname><given-names>N</given-names></name><name><surname>Jones</surname><given-names>DTW</given-names></name><name><surname>Jones</surname><given-names>D</given-names></name><name><surname>Knappskog</surname><given-names>S</given-names></name><name><surname>Kool</surname><given-names>M</given-names></name><name><surname>Lakhani</surname><given-names>SR</given-names></name><name><surname>López-Otín</surname><given-names>C</given-names></name><name><surname>Martin</surname><given-names>S</given-names></name><name><surname>Munshi</surname><given-names>NC</given-names></name><name><surname>Nakamura</surname><given-names>H</given-names></name><name><surname>Northcott</surname><given-names>PA</given-names></name><name><surname>Pajic</surname><given-names>M</given-names></name><name><surname>Papaemmanuil</surname><given-names>E</given-names></name><name><surname>Paradiso</surname><given-names>A</given-names></name><name><surname>Pearson</surname><given-names>JV</given-names></name><name><surname>Puente</surname><given-names>XS</given-names></name><name><surname>Raine</surname><given-names>K</given-names></name><name><surname>Ramakrishna</surname><given-names>M</given-names></name><name><surname>Richardson</surname><given-names>AL</given-names></name><name><surname>Richter</surname><given-names>J</given-names></name><name><surname>Rosenstiel</surname><given-names>P</given-names></name><name><surname>Schlesner</surname><given-names>M</given-names></name><name><surname>Schumacher</surname><given-names>TN</given-names></name><name><surname>Span</surname><given-names>PN</given-names></name><name><surname>Teague</surname><given-names>JW</given-names></name><name><surname>Totoki</surname><given-names>Y</given-names></name><name><surname>Tutt</surname><given-names>ANJ</given-names></name><name><surname>Valdés-Mas</surname><given-names>R</given-names></name><name><surname>van Buuren</surname><given-names>MM</given-names></name><name><surname>van ’t Veer</surname><given-names>L</given-names></name><name><surname>Vincent-Salomon</surname><given-names>A</given-names></name><name><surname>Waddell</surname><given-names>N</given-names></name><name><surname>Yates</surname><given-names>LR</given-names></name><collab>Australian Pancreatic Cancer Genome Initiative</collab><collab>ICGC Breast Cancer Consortium</collab><collab>ICGC MMML-Seq Consortium</collab><collab>ICGC PedBrain</collab><name><surname>Zucman-Rossi</surname><given-names>J</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>McDermott</surname><given-names>U</given-names></name><name><surname>Lichter</surname><given-names>P</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name><name><surname>Grimmond</surname><given-names>SM</given-names></name><name><surname>Siebert</surname><given-names>R</given-names></name><name><surname>Campo</surname><given-names>E</given-names></name><name><surname>Shibata</surname><given-names>T</given-names></name><name><surname>Pfister</surname><given-names>SM</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Signatures of mutational processes in human cancer</article-title><source>Nature</source><volume>500</volume><fpage>415</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1038/nature12477</pub-id><pub-id pub-id-type="pmid">23945592</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boeva</surname><given-names>V</given-names></name><name><surname>Popova</surname><given-names>T</given-names></name><name><surname>Bleakley</surname><given-names>K</given-names></name><name><surname>Chiche</surname><given-names>P</given-names></name><name><surname>Cappo</surname><given-names>J</given-names></name><name><surname>Schleiermacher</surname><given-names>G</given-names></name><name><surname>Janoueix-Lerosey</surname><given-names>I</given-names></name><name><surname>Delattre</surname><given-names>O</given-names></name><name><surname>Barillot</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data</article-title><source>Bioinformatics</source><volume>28</volume><fpage>423</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btr670</pub-id><pub-id pub-id-type="pmid">22155870</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Torre</surname><given-names>LA</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA</source><volume>68</volume><fpage>394</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.3322/caac.21492</pub-id><pub-id pub-id-type="pmid">30207593</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bridgewater</surname><given-names>J</given-names></name><name><surname>Galle</surname><given-names>PR</given-names></name><name><surname>Khan</surname><given-names>SA</given-names></name><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Park</surname><given-names>J-W</given-names></name><name><surname>Patel</surname><given-names>T</given-names></name><name><surname>Pawlik</surname><given-names>TM</given-names></name><name><surname>Gores</surname><given-names>GJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma</article-title><source>Journal of Hepatology</source><volume>60</volume><fpage>1268</fpage><lpage>1289</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2014.01.021</pub-id><pub-id pub-id-type="pmid">24681130</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Celik</surname><given-names>H</given-names></name><name><surname>Koh</surname><given-names>WK</given-names></name><name><surname>Kramer</surname><given-names>AC</given-names></name><name><surname>Ostrander</surname><given-names>EL</given-names></name><name><surname>Mallaney</surname><given-names>C</given-names></name><name><surname>Fisher</surname><given-names>DAC</given-names></name><name><surname>Xiang</surname><given-names>J</given-names></name><name><surname>Wilson</surname><given-names>WC</given-names></name><name><surname>Martens</surname><given-names>A</given-names></name><name><surname>Kothari</surname><given-names>A</given-names></name><name><surname>Fishberger</surname><given-names>G</given-names></name><name><surname>Tycksen</surname><given-names>E</given-names></name><name><surname>Karpova</surname><given-names>D</given-names></name><name><surname>Duncavage</surname><given-names>EJ</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Oh</surname><given-names>ST</given-names></name><name><surname>Challen</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Jarid2 functions as a tumor suppressor in myeloid neoplasms by repressing self-renewal in hematopoietic progenitor cells</article-title><source>Cancer Cell</source><volume>34</volume><fpage>741</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2018.10.008</pub-id><pub-id pub-id-type="pmid">30423295</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerami</surname><given-names>E</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Dogrusoz</surname><given-names>U</given-names></name><name><surname>Gross</surname><given-names>BE</given-names></name><name><surname>Sumer</surname><given-names>SO</given-names></name><name><surname>Aksoy</surname><given-names>BA</given-names></name><name><surname>Jacobsen</surname><given-names>A</given-names></name><name><surname>Byrne</surname><given-names>CJ</given-names></name><name><surname>Heuer</surname><given-names>ML</given-names></name><name><surname>Larsson</surname><given-names>E</given-names></name><name><surname>Antipin</surname><given-names>Y</given-names></name><name><surname>Reva</surname><given-names>B</given-names></name><name><surname>Goldberg</surname><given-names>AP</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The cbio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data</article-title><source>Cancer Discovery</source><volume>2</volume><fpage>401</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0095</pub-id><pub-id pub-id-type="pmid">22588877</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X-X</given-names></name><name><surname>Zhong</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>S-M</given-names></name><name><surname>Chen</surname><given-names>Z-H</given-names></name><name><surname>Jin</surname><given-names>S-Z</given-names></name><name><surname>Xia</surname><given-names>T-L</given-names></name><name><surname>Li</surname><given-names>R-Y</given-names></name><name><surname>Zhou</surname><given-names>A-J</given-names></name><name><surname>Su</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>Y-H</given-names></name><name><surname>Huang</surname><given-names>Q-T</given-names></name><name><surname>Huang</surname><given-names>L-Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Y-N</given-names></name><name><surname>Yun</surname><given-names>J-P</given-names></name><name><surname>Wu</surname><given-names>Q-L</given-names></name><name><surname>Lin</surname><given-names>D-X</given-names></name><name><surname>Bai</surname><given-names>F</given-names></name><name><surname>Zeng</surname><given-names>M-S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genomic comparison of esophageal squamous cell carcinoma and its precursor lesions by multi-region whole-exome sequencing</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>524</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-00650-0</pub-id><pub-id pub-id-type="pmid">28900112</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>KJ</given-names></name><name><surname>Ewald</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A collective route to metastasis: seeding by tumor cell clusters</article-title><source>Science</source><volume>352</volume><fpage>167</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1126/science.aaf6546</pub-id><pub-id pub-id-type="pmid">27124449</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>A</given-names></name><name><surname>Gao</surname><given-names>R</given-names></name><name><surname>Navin</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Tumor evolution: linear, branching, neutral or punctuated?</article-title><source>Biochimica et Biophysica Acta. Reviews on Cancer</source><volume>1867</volume><fpage>151</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/j.bbcan.2017.01.003</pub-id><pub-id pub-id-type="pmid">28110020</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Debelle</surname><given-names>FD</given-names></name><name><surname>Vanherweghem</surname><given-names>JL</given-names></name><name><surname>Nortier</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Aristolochic acid nephropathy: a worldwide problem</article-title><source>Kidney International</source><volume>74</volume><fpage>158</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1038/ki.2008.129</pub-id><pub-id pub-id-type="pmid">18418355</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Degasperi</surname><given-names>A</given-names></name><name><surname>Amarante</surname><given-names>TD</given-names></name><name><surname>Czarnecki</surname><given-names>J</given-names></name><name><surname>Shooter</surname><given-names>S</given-names></name><name><surname>Zou</surname><given-names>X</given-names></name><name><surname>Glodzik</surname><given-names>D</given-names></name><name><surname>Morganella</surname><given-names>S</given-names></name><name><surname>Nanda</surname><given-names>AS</given-names></name><name><surname>Badja</surname><given-names>C</given-names></name><name><surname>Koh</surname><given-names>G</given-names></name><name><surname>Momen</surname><given-names>SE</given-names></name><name><surname>Georgakopoulos-Soares</surname><given-names>I</given-names></name><name><surname>Dias</surname><given-names>JML</given-names></name><name><surname>Young</surname><given-names>J</given-names></name><name><surname>Memari</surname><given-names>Y</given-names></name><name><surname>Davies</surname><given-names>H</given-names></name><name><surname>Nik-Zainal</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A practical framework and online tool for mutational signature analyses show Inter-tissue variation and driver dependencies</article-title><source>Nature Cancer</source><volume>1</volume><fpage>249</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1038/s43018-020-0027-5</pub-id><pub-id pub-id-type="pmid">32118208</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Díaz-Gay</surname><given-names>M</given-names></name><name><surname>Vila-Casadesús</surname><given-names>M</given-names></name><name><surname>Franch-Expósito</surname><given-names>S</given-names></name><name><surname>Hernández-Illán</surname><given-names>E</given-names></name><name><surname>Lozano</surname><given-names>JJ</given-names></name><name><surname>Castellví-Bel</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mutational signatures in cancer (musica): a web application to implement mutational signatures analysis in cancer samples</article-title><source>BMC Bioinformatics</source><volume>19</volume><elocation-id>224</elocation-id><pub-id pub-id-type="doi">10.1186/s12859-018-2234-y</pub-id><pub-id pub-id-type="pmid">29898651</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Favero</surname><given-names>F</given-names></name><name><surname>Joshi</surname><given-names>T</given-names></name><name><surname>Marquard</surname><given-names>AM</given-names></name><name><surname>Birkbak</surname><given-names>NJ</given-names></name><name><surname>Krzystanek</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Szallasi</surname><given-names>Z</given-names></name><name><surname>Eklund</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data</article-title><source>Annals of Oncology</source><volume>26</volume><fpage>64</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdu479</pub-id><pub-id pub-id-type="pmid">25319062</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foulkes</surname><given-names>WD</given-names></name><name><surname>Priest</surname><given-names>JR</given-names></name><name><surname>Duchaine</surname><given-names>TF</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Dicer1: mutations, microRNAs and mechanisms</article-title><source>Nature Reviews Cancer</source><volume>14</volume><fpage>662</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1038/nrc3802</pub-id><pub-id pub-id-type="pmid">25176334</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gara</surname><given-names>RK</given-names></name><name><surname>Kumari</surname><given-names>S</given-names></name><name><surname>Ganju</surname><given-names>A</given-names></name><name><surname>Yallapu</surname><given-names>MM</given-names></name><name><surname>Jaggi</surname><given-names>M</given-names></name><name><surname>Chauhan</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Slit/robo pathway: a promising therapeutic target for cancer</article-title><source>Drug Discovery Today</source><volume>20</volume><fpage>156</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2014.09.008</pub-id><pub-id pub-id-type="pmid">25245168</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gara</surname><given-names>SK</given-names></name><name><surname>Lack</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Harris</surname><given-names>E</given-names></name><name><surname>Cam</surname><given-names>M</given-names></name><name><surname>Kebebew</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>4172</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-06366-z</pub-id><pub-id pub-id-type="pmid">30301885</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greaves</surname><given-names>M</given-names></name><name><surname>Maley</surname><given-names>CC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Clonal evolution in cancer</article-title><source>Nature</source><volume>481</volume><fpage>306</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1038/nature10762</pub-id><pub-id pub-id-type="pmid">22258609</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griner</surname><given-names>EM</given-names></name><name><surname>Kazanietz</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Protein kinase C and other diacylglycerol effectors in cancer</article-title><source>Nature Reviews. Cancer</source><volume>7</volume><fpage>281</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1038/nrc2110</pub-id><pub-id pub-id-type="pmid">17384583</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gundem</surname><given-names>G</given-names></name><name><surname>Van Loo</surname><given-names>P</given-names></name><name><surname>Kremeyer</surname><given-names>B</given-names></name><name><surname>Alexandrov</surname><given-names>LB</given-names></name><name><surname>Tubio</surname><given-names>JMC</given-names></name><name><surname>Papaemmanuil</surname><given-names>E</given-names></name><name><surname>Brewer</surname><given-names>DS</given-names></name><name><surname>Kallio</surname><given-names>HML</given-names></name><name><surname>Högnäs</surname><given-names>G</given-names></name><name><surname>Annala</surname><given-names>M</given-names></name><name><surname>Kivinummi</surname><given-names>K</given-names></name><name><surname>Goody</surname><given-names>V</given-names></name><name><surname>Latimer</surname><given-names>C</given-names></name><name><surname>O’Meara</surname><given-names>S</given-names></name><name><surname>Dawson</surname><given-names>KJ</given-names></name><name><surname>Isaacs</surname><given-names>W</given-names></name><name><surname>Emmert-Buck</surname><given-names>MR</given-names></name><name><surname>Nykter</surname><given-names>M</given-names></name><name><surname>Foster</surname><given-names>C</given-names></name><name><surname>Kote-Jarai</surname><given-names>Z</given-names></name><name><surname>Easton</surname><given-names>D</given-names></name><name><surname>Whitaker</surname><given-names>HC</given-names></name><collab>ICGC Prostate Group</collab><name><surname>Neal</surname><given-names>DE</given-names></name><name><surname>Cooper</surname><given-names>CS</given-names></name><name><surname>Eeles</surname><given-names>RA</given-names></name><name><surname>Visakorpi</surname><given-names>T</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>McDermott</surname><given-names>U</given-names></name><name><surname>Wedge</surname><given-names>DC</given-names></name><name><surname>Bova</surname><given-names>GS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The evolutionary history of lethal metastatic prostate cancer</article-title><source>Nature</source><volume>520</volume><fpage>353</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1038/nature14347</pub-id><pub-id pub-id-type="pmid">25830880</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoang</surname><given-names>ML</given-names></name><name><surname>Chen</surname><given-names>CH</given-names></name><name><surname>Sidorenko</surname><given-names>VS</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Dickman</surname><given-names>KG</given-names></name><name><surname>Yun</surname><given-names>BH</given-names></name><name><surname>Moriya</surname><given-names>M</given-names></name><name><surname>Niknafs</surname><given-names>N</given-names></name><name><surname>Douville</surname><given-names>C</given-names></name><name><surname>Karchin</surname><given-names>R</given-names></name><name><surname>Turesky</surname><given-names>RJ</given-names></name><name><surname>Pu</surname><given-names>YS</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Papadopoulos</surname><given-names>N</given-names></name><name><surname>Grollman</surname><given-names>AP</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Rosenquist</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing</article-title><source>Science Translational Medicine</source><volume>5</volume><elocation-id>197</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.3006200</pub-id><pub-id pub-id-type="pmid">23926200</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>MKH</given-names></name><name><surname>Macintyre</surname><given-names>G</given-names></name><name><surname>Wedge</surname><given-names>DC</given-names></name><name><surname>Van Loo</surname><given-names>P</given-names></name><name><surname>Patel</surname><given-names>K</given-names></name><name><surname>Lunke</surname><given-names>S</given-names></name><name><surname>Alexandrov</surname><given-names>LB</given-names></name><name><surname>Sloggett</surname><given-names>C</given-names></name><name><surname>Cmero</surname><given-names>M</given-names></name><name><surname>Marass</surname><given-names>F</given-names></name><name><surname>Tsui</surname><given-names>D</given-names></name><name><surname>Mangiola</surname><given-names>S</given-names></name><name><surname>Lonie</surname><given-names>A</given-names></name><name><surname>Naeem</surname><given-names>H</given-names></name><name><surname>Sapre</surname><given-names>N</given-names></name><name><surname>Phal</surname><given-names>PM</given-names></name><name><surname>Kurganovs</surname><given-names>N</given-names></name><name><surname>Chin</surname><given-names>X</given-names></name><name><surname>Kerger</surname><given-names>M</given-names></name><name><surname>Warren</surname><given-names>AY</given-names></name><name><surname>Neal</surname><given-names>D</given-names></name><name><surname>Gnanapragasam</surname><given-names>V</given-names></name><name><surname>Rosenfeld</surname><given-names>N</given-names></name><name><surname>Pedersen</surname><given-names>JS</given-names></name><name><surname>Ryan</surname><given-names>A</given-names></name><name><surname>Haviv</surname><given-names>I</given-names></name><name><surname>Costello</surname><given-names>AJ</given-names></name><name><surname>Corcoran</surname><given-names>NM</given-names></name><name><surname>Hovens</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>6605</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms7605</pub-id><pub-id pub-id-type="pmid">25827447</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ignatiadis</surname><given-names>M</given-names></name><name><surname>Sledge</surname><given-names>GW</given-names></name><name><surname>Jeffrey</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Liquid biopsy enters the clinic-implementation issues and future challenges</article-title><source>Nature Reviews. Clinical Oncology</source><volume>18</volume><fpage>297</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1038/s41571-020-00457-x</pub-id><pub-id pub-id-type="pmid">33473219</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamal-Hanjani</surname><given-names>M</given-names></name><name><surname>Wilson</surname><given-names>GA</given-names></name><name><surname>McGranahan</surname><given-names>N</given-names></name><name><surname>Birkbak</surname><given-names>NJ</given-names></name><name><surname>Watkins</surname><given-names>TBK</given-names></name><name><surname>Veeriah</surname><given-names>S</given-names></name><name><surname>Shafi</surname><given-names>S</given-names></name><name><surname>Johnson</surname><given-names>DH</given-names></name><name><surname>Mitter</surname><given-names>R</given-names></name><name><surname>Rosenthal</surname><given-names>R</given-names></name><name><surname>Salm</surname><given-names>M</given-names></name><name><surname>Horswell</surname><given-names>S</given-names></name><name><surname>Escudero</surname><given-names>M</given-names></name><name><surname>Matthews</surname><given-names>N</given-names></name><name><surname>Rowan</surname><given-names>A</given-names></name><name><surname>Chambers</surname><given-names>T</given-names></name><name><surname>Moore</surname><given-names>DA</given-names></name><name><surname>Turajlic</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>S-M</given-names></name><name><surname>Forster</surname><given-names>MD</given-names></name><name><surname>Ahmad</surname><given-names>T</given-names></name><name><surname>Hiley</surname><given-names>CT</given-names></name><name><surname>Abbosh</surname><given-names>C</given-names></name><name><surname>Falzon</surname><given-names>M</given-names></name><name><surname>Borg</surname><given-names>E</given-names></name><name><surname>Marafioti</surname><given-names>T</given-names></name><name><surname>Lawrence</surname><given-names>D</given-names></name><name><surname>Hayward</surname><given-names>M</given-names></name><name><surname>Kolvekar</surname><given-names>S</given-names></name><name><surname>Panagiotopoulos</surname><given-names>N</given-names></name><name><surname>Janes</surname><given-names>SM</given-names></name><name><surname>Thakrar</surname><given-names>R</given-names></name><name><surname>Ahmed</surname><given-names>A</given-names></name><name><surname>Blackhall</surname><given-names>F</given-names></name><name><surname>Summers</surname><given-names>Y</given-names></name><name><surname>Shah</surname><given-names>R</given-names></name><name><surname>Joseph</surname><given-names>L</given-names></name><name><surname>Quinn</surname><given-names>AM</given-names></name><name><surname>Crosbie</surname><given-names>PA</given-names></name><name><surname>Naidu</surname><given-names>B</given-names></name><name><surname>Middleton</surname><given-names>G</given-names></name><name><surname>Langman</surname><given-names>G</given-names></name><name><surname>Trotter</surname><given-names>S</given-names></name><name><surname>Nicolson</surname><given-names>M</given-names></name><name><surname>Remmen</surname><given-names>H</given-names></name><name><surname>Kerr</surname><given-names>K</given-names></name><name><surname>Chetty</surname><given-names>M</given-names></name><name><surname>Gomersall</surname><given-names>L</given-names></name><name><surname>Fennell</surname><given-names>DA</given-names></name><name><surname>Nakas</surname><given-names>A</given-names></name><name><surname>Rathinam</surname><given-names>S</given-names></name><name><surname>Anand</surname><given-names>G</given-names></name><name><surname>Khan</surname><given-names>S</given-names></name><name><surname>Russell</surname><given-names>P</given-names></name><name><surname>Ezhil</surname><given-names>V</given-names></name><name><surname>Ismail</surname><given-names>B</given-names></name><name><surname>Irvin-Sellers</surname><given-names>M</given-names></name><name><surname>Prakash</surname><given-names>V</given-names></name><name><surname>Lester</surname><given-names>JF</given-names></name><name><surname>Kornaszewska</surname><given-names>M</given-names></name><name><surname>Attanoos</surname><given-names>R</given-names></name><name><surname>Adams</surname><given-names>H</given-names></name><name><surname>Davies</surname><given-names>H</given-names></name><name><surname>Dentro</surname><given-names>S</given-names></name><name><surname>Taniere</surname><given-names>P</given-names></name><name><surname>O’Sullivan</surname><given-names>B</given-names></name><name><surname>Lowe</surname><given-names>HL</given-names></name><name><surname>Hartley</surname><given-names>JA</given-names></name><name><surname>Iles</surname><given-names>N</given-names></name><name><surname>Bell</surname><given-names>H</given-names></name><name><surname>Ngai</surname><given-names>Y</given-names></name><name><surname>Shaw</surname><given-names>JA</given-names></name><name><surname>Herrero</surname><given-names>J</given-names></name><name><surname>Szallasi</surname><given-names>Z</given-names></name><name><surname>Schwarz</surname><given-names>RF</given-names></name><name><surname>Stewart</surname><given-names>A</given-names></name><name><surname>Quezada</surname><given-names>SA</given-names></name><name><surname>Le Quesne</surname><given-names>J</given-names></name><name><surname>Van Loo</surname><given-names>P</given-names></name><name><surname>Dive</surname><given-names>C</given-names></name><name><surname>Hackshaw</surname><given-names>A</given-names></name><name><surname>Swanton</surname><given-names>C</given-names></name><collab>TRACERx Consortium</collab></person-group><year iso-8601-date="2017">2017</year><article-title>Tracking the evolution of non-small-cell lung cancer</article-title><source>The New England Journal of Medicine</source><volume>376</volume><fpage>2109</fpage><lpage>2121</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1616288</pub-id><pub-id pub-id-type="pmid">28445112</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kakiuchi</surname><given-names>N</given-names></name><name><surname>Yoshida</surname><given-names>K</given-names></name><name><surname>Uchino</surname><given-names>M</given-names></name><name><surname>Kihara</surname><given-names>T</given-names></name><name><surname>Akaki</surname><given-names>K</given-names></name><name><surname>Inoue</surname><given-names>Y</given-names></name><name><surname>Kawada</surname><given-names>K</given-names></name><name><surname>Nagayama</surname><given-names>S</given-names></name><name><surname>Yokoyama</surname><given-names>A</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Matsuura</surname><given-names>M</given-names></name><name><surname>Horimatsu</surname><given-names>T</given-names></name><name><surname>Hirano</surname><given-names>T</given-names></name><name><surname>Goto</surname><given-names>N</given-names></name><name><surname>Takeuchi</surname><given-names>Y</given-names></name><name><surname>Ochi</surname><given-names>Y</given-names></name><name><surname>Shiozawa</surname><given-names>Y</given-names></name><name><surname>Kogure</surname><given-names>Y</given-names></name><name><surname>Watatani</surname><given-names>Y</given-names></name><name><surname>Fujii</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>SK</given-names></name><name><surname>Kon</surname><given-names>A</given-names></name><name><surname>Kataoka</surname><given-names>K</given-names></name><name><surname>Yoshizato</surname><given-names>T</given-names></name><name><surname>Nakagawa</surname><given-names>MM</given-names></name><name><surname>Yoda</surname><given-names>A</given-names></name><name><surname>Nanya</surname><given-names>Y</given-names></name><name><surname>Makishima</surname><given-names>H</given-names></name><name><surname>Shiraishi</surname><given-names>Y</given-names></name><name><surname>Chiba</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Sanada</surname><given-names>M</given-names></name><name><surname>Sugihara</surname><given-names>E</given-names></name><name><surname>Sato</surname><given-names>T-A</given-names></name><name><surname>Maruyama</surname><given-names>T</given-names></name><name><surname>Miyoshi</surname><given-names>H</given-names></name><name><surname>Taketo</surname><given-names>MM</given-names></name><name><surname>Oishi</surname><given-names>J</given-names></name><name><surname>Inagaki</surname><given-names>R</given-names></name><name><surname>Ueda</surname><given-names>Y</given-names></name><name><surname>Okamoto</surname><given-names>S</given-names></name><name><surname>Okajima</surname><given-names>H</given-names></name><name><surname>Sakai</surname><given-names>Y</given-names></name><name><surname>Sakurai</surname><given-names>T</given-names></name><name><surname>Haga</surname><given-names>H</given-names></name><name><surname>Hirota</surname><given-names>S</given-names></name><name><surname>Ikeuchi</surname><given-names>H</given-names></name><name><surname>Nakase</surname><given-names>H</given-names></name><name><surname>Marusawa</surname><given-names>H</given-names></name><name><surname>Chiba</surname><given-names>T</given-names></name><name><surname>Takeuchi</surname><given-names>O</given-names></name><name><surname>Miyano</surname><given-names>S</given-names></name><name><surname>Seno</surname><given-names>H</given-names></name><name><surname>Ogawa</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Frequent mutations that converge on the NFKBIZ pathway in ulcerative colitis</article-title><source>Nature</source><volume>577</volume><fpage>260</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1856-1</pub-id><pub-id pub-id-type="pmid">31853061</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Khanna</surname><given-names>A</given-names></name><name><surname>Larson</surname><given-names>D</given-names></name><name><surname>Srivatsan</surname><given-names>S</given-names></name><name><surname>Mosior</surname><given-names>M</given-names></name><name><surname>Abbott</surname><given-names>T</given-names></name><name><surname>Kiwala</surname><given-names>S</given-names></name><name><surname>Ley</surname><given-names>T</given-names></name><name><surname>Duncavage</surname><given-names>E</given-names></name><name><surname>Walter</surname><given-names>M</given-names></name><name><surname>Walker</surname><given-names>J</given-names></name><name><surname>Griffith</surname><given-names>O</given-names></name><name><surname>Griffith</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022a</year><data-title>bam-readcount</data-title><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/genome/bam-readcount">https://github.com/genome/bam-readcount</ext-link></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khanna</surname><given-names>A</given-names></name><name><surname>Larson</surname><given-names>D</given-names></name><name><surname>Srivatsan</surname><given-names>S</given-names></name><name><surname>Mosior</surname><given-names>M</given-names></name><name><surname>Abbott</surname><given-names>T</given-names></name><name><surname>Kiwala</surname><given-names>S</given-names></name><name><surname>Ley</surname><given-names>T</given-names></name><name><surname>Duncavage</surname><given-names>E</given-names></name><name><surname>Walter</surname><given-names>M</given-names></name><name><surname>Walker</surname><given-names>J</given-names></name><name><surname>Griffith</surname><given-names>O</given-names></name><name><surname>Griffith</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022b</year><article-title>Bam-readcount - rapid generation of basepair-resolution sequence metrics</article-title><source>Journal of Open Source Software</source><volume>7</volume><elocation-id>3722</elocation-id><pub-id pub-id-type="doi">10.21105/joss.03722</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koh</surname><given-names>J</given-names></name><name><surname>Nam</surname><given-names>SK</given-names></name><name><surname>Lee</surname><given-names>YW</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Lee</surname><given-names>K-W</given-names></name><name><surname>Ock</surname><given-names>C-Y</given-names></name><name><surname>Oh</surname><given-names>D-Y</given-names></name><name><surname>Ahn</surname><given-names>S-H</given-names></name><name><surname>Kim</surname><given-names>H-H</given-names></name><name><surname>Kang</surname><given-names>K-W</given-names></name><name><surname>Kim</surname><given-names>WH</given-names></name><name><surname>Lee</surname><given-names>H-Y</given-names></name><name><surname>Lee</surname><given-names>HS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Trastuzumab specific epitope evaluation as a predictive and prognostic biomarker in gastric cancer patients</article-title><source>Biomolecules</source><volume>9</volume><elocation-id>782</elocation-id><pub-id pub-id-type="doi">10.3390/biom9120782</pub-id><pub-id pub-id-type="pmid">31779184</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>AJ</given-names></name><name><surname>Lee</surname><given-names>J-K</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Kwon</surname><given-names>Y</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Chun</surname><given-names>H</given-names></name><name><surname>Ju</surname><given-names>YS</given-names></name><name><surname>Hong</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mutalisk: a web-based somatic mutation analyis toolkit for genomic, transcriptional and epigenomic signatures</article-title><source>Nucleic Acids Research</source><volume>46</volume><fpage>W102</fpage><lpage>W108</lpage><pub-id pub-id-type="doi">10.1093/nar/gky406</pub-id><pub-id pub-id-type="pmid">29790943</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data</article-title><source>Bioinformatics</source><volume>27</volume><fpage>2987</fpage><lpage>2993</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btr509</pub-id><pub-id pub-id-type="pmid">21903627</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ye</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Tan</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Shen</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>X-A</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Qu</surname><given-names>K</given-names></name><name><surname>Ding</surname><given-names>Q</given-names></name><name><surname>Weng</surname><given-names>H</given-names></name><name><surname>Ding</surname><given-names>Q</given-names></name><name><surname>Mu</surname><given-names>J</given-names></name><name><surname>Shu</surname><given-names>Y</given-names></name><name><surname>Bao</surname><given-names>R</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>P</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Gong</surname><given-names>W</given-names></name><name><surname>Tang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Chin</surname><given-names>YE</given-names></name><name><surname>Weng</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Whole-Exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway</article-title><source>Nature Genetics</source><volume>46</volume><fpage>872</fpage><lpage>876</lpage><pub-id pub-id-type="doi">10.1038/ng.3030</pub-id><pub-id pub-id-type="pmid">24997986</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Qu</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Bai</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>R</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Xiang</surname><given-names>S</given-names></name><name><surname>Ye</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Gong</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Genomic ErbB2/ErbB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis</article-title><source>Gut</source><volume>68</volume><fpage>1024</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2018-316039</pub-id><pub-id pub-id-type="pmid">29954840</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>X</given-names></name><name><surname>Dong</surname><given-names>K</given-names></name><name><surname>Long</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Mao</surname><given-names>Y</given-names></name><name><surname>Sang</surname><given-names>X</given-names></name><name><surname>Ji</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Genomic characterization of co-existing neoplasia and carcinoma lesions reveals distinct evolutionary paths of gallbladder cancer</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>4753</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-25012-9</pub-id><pub-id pub-id-type="pmid">34362903</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malikic</surname><given-names>S</given-names></name><name><surname>McPherson</surname><given-names>AW</given-names></name><name><surname>Donmez</surname><given-names>N</given-names></name><name><surname>Sahinalp</surname><given-names>CS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Clonality inference in multiple tumor samples using phylogeny</article-title><source>Bioinformatics</source><volume>31</volume><fpage>1349</fpage><lpage>1356</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btv003</pub-id><pub-id pub-id-type="pmid">25568283</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marusyk</surname><given-names>A</given-names></name><name><surname>Almendro</surname><given-names>V</given-names></name><name><surname>Polyak</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Intra-Tumour heterogeneity: a looking glass for cancer?</article-title><source>Nature Reviews. Cancer</source><volume>12</volume><fpage>323</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1038/nrc3261</pub-id><pub-id pub-id-type="pmid">22513401</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merlo</surname><given-names>LMF</given-names></name><name><surname>Pepper</surname><given-names>JW</given-names></name><name><surname>Reid</surname><given-names>BJ</given-names></name><name><surname>Maley</surname><given-names>CC</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Cancer as an evolutionary and ecological process</article-title><source>Nature Reviews. Cancer</source><volume>6</volume><fpage>924</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.1038/nrc2013</pub-id><pub-id pub-id-type="pmid">17109012</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minussi</surname><given-names>DC</given-names></name><name><surname>Nicholson</surname><given-names>MD</given-names></name><name><surname>Ye</surname><given-names>H</given-names></name><name><surname>Davis</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Baker</surname><given-names>T</given-names></name><name><surname>Tarabichi</surname><given-names>M</given-names></name><name><surname>Sei</surname><given-names>E</given-names></name><name><surname>Du</surname><given-names>H</given-names></name><name><surname>Rabbani</surname><given-names>M</given-names></name><name><surname>Peng</surname><given-names>C</given-names></name><name><surname>Hu</surname><given-names>M</given-names></name><name><surname>Bai</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>Y-W</given-names></name><name><surname>Schalck</surname><given-names>A</given-names></name><name><surname>Multani</surname><given-names>A</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>McDonald</surname><given-names>TO</given-names></name><name><surname>Casasent</surname><given-names>A</given-names></name><name><surname>Barrera</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Lim</surname><given-names>B</given-names></name><name><surname>Arun</surname><given-names>B</given-names></name><name><surname>Meric-Bernstam</surname><given-names>F</given-names></name><name><surname>Van Loo</surname><given-names>P</given-names></name><name><surname>Michor</surname><given-names>F</given-names></name><name><surname>Navin</surname><given-names>NE</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Breast tumours maintain a reservoir of subclonal diversity during expansion</article-title><source>Nature</source><volume>592</volume><fpage>302</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03357-x</pub-id><pub-id pub-id-type="pmid">33762732</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>H</given-names></name><name><surname>Arai</surname><given-names>Y</given-names></name><name><surname>Totoki</surname><given-names>Y</given-names></name><name><surname>Shirota</surname><given-names>T</given-names></name><name><surname>Elzawahry</surname><given-names>A</given-names></name><name><surname>Kato</surname><given-names>M</given-names></name><name><surname>Hama</surname><given-names>N</given-names></name><name><surname>Hosoda</surname><given-names>F</given-names></name><name><surname>Urushidate</surname><given-names>T</given-names></name><name><surname>Ohashi</surname><given-names>S</given-names></name><name><surname>Hiraoka</surname><given-names>N</given-names></name><name><surname>Ojima</surname><given-names>H</given-names></name><name><surname>Shimada</surname><given-names>K</given-names></name><name><surname>Okusaka</surname><given-names>T</given-names></name><name><surname>Kosuge</surname><given-names>T</given-names></name><name><surname>Miyagawa</surname><given-names>S</given-names></name><name><surname>Shibata</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Genomic spectra of biliary tract cancer</article-title><source>Nature Genetics</source><volume>47</volume><fpage>1003</fpage><lpage>1010</lpage><pub-id pub-id-type="doi">10.1038/ng.3375</pub-id><pub-id pub-id-type="pmid">26258846</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakazawa</surname><given-names>K</given-names></name><name><surname>Dobashi</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>S</given-names></name><name><surname>Fujii</surname><given-names>H</given-names></name><name><surname>Takeda</surname><given-names>Y</given-names></name><name><surname>Ooi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-Met in biliary tract cancers</article-title><source>The Journal of Pathology</source><volume>206</volume><fpage>356</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1002/path.1779</pub-id><pub-id pub-id-type="pmid">15892172</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nam</surname><given-names>A-R</given-names></name><name><surname>Kim</surname><given-names>J-W</given-names></name><name><surname>Cha</surname><given-names>Y</given-names></name><name><surname>Ha</surname><given-names>H</given-names></name><name><surname>Park</surname><given-names>JE</given-names></name><name><surname>Bang</surname><given-names>J-H</given-names></name><name><surname>Jin</surname><given-names>MH</given-names></name><name><surname>Lee</surname><given-names>K-H</given-names></name><name><surname>Kim</surname><given-names>T-Y</given-names></name><name><surname>Han</surname><given-names>S-W</given-names></name><name><surname>Im</surname><given-names>S-A</given-names></name><name><surname>Kim</surname><given-names>T-Y</given-names></name><name><surname>Oh</surname><given-names>D-Y</given-names></name><name><surname>Bang</surname><given-names>Y-J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Therapeutic implication of HER2 in advanced biliary tract cancer</article-title><source>Oncotarget</source><volume>7</volume><fpage>58007</fpage><lpage>58021</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.11157</pub-id><pub-id pub-id-type="pmid">27517322</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narayan</surname><given-names>RR</given-names></name><name><surname>Creasy</surname><given-names>JM</given-names></name><name><surname>Goldman</surname><given-names>DA</given-names></name><name><surname>Gönen</surname><given-names>M</given-names></name><name><surname>Kandoth</surname><given-names>C</given-names></name><name><surname>Kundra</surname><given-names>R</given-names></name><name><surname>Solit</surname><given-names>DB</given-names></name><name><surname>Askan</surname><given-names>G</given-names></name><name><surname>Klimstra</surname><given-names>DS</given-names></name><name><surname>Basturk</surname><given-names>O</given-names></name><name><surname>Allen</surname><given-names>PJ</given-names></name><name><surname>Balachandran</surname><given-names>VP</given-names></name><name><surname>D’Angelica</surname><given-names>MI</given-names></name><name><surname>DeMatteo</surname><given-names>RP</given-names></name><name><surname>Drebin</surname><given-names>JA</given-names></name><name><surname>Kingham</surname><given-names>TP</given-names></name><name><surname>Simpson</surname><given-names>AL</given-names></name><name><surname>Abou-Alfa</surname><given-names>GK</given-names></name><name><surname>Harding</surname><given-names>JJ</given-names></name><name><surname>O’Reilly</surname><given-names>EM</given-names></name><name><surname>Butte</surname><given-names>JM</given-names></name><name><surname>Matsuyama</surname><given-names>R</given-names></name><name><surname>Endo</surname><given-names>I</given-names></name><name><surname>Jarnagin</surname><given-names>WR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Regional differences in gallbladder cancer pathogenesis: insights from a multi-institutional comparison of tumor mutations</article-title><source>Cancer</source><volume>125</volume><fpage>575</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1002/cncr.31850</pub-id><pub-id pub-id-type="pmid">30427539</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nepal</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name><name><surname>O’Rourke</surname><given-names>CJ</given-names></name><name><surname>Bhatt</surname><given-names>DK</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Van Dyke</surname><given-names>AL</given-names></name><name><surname>Choo-Wosoba</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Hildesheim</surname><given-names>A</given-names></name><name><surname>Goldstein</surname><given-names>AM</given-names></name><name><surname>Dean</surname><given-names>M</given-names></name><name><surname>LaFuente-Barquero</surname><given-names>J</given-names></name><name><surname>Lawrence</surname><given-names>S</given-names></name><name><surname>Mutreja</surname><given-names>K</given-names></name><name><surname>Olanich</surname><given-names>ME</given-names></name><name><surname>Lorenzo Bermejo</surname><given-names>J</given-names></name><collab>CGR Exome Studies Group</collab><name><surname>Ferreccio</surname><given-names>C</given-names></name><name><surname>Roa</surname><given-names>JC</given-names></name><name><surname>Rashid</surname><given-names>A</given-names></name><name><surname>Hsing</surname><given-names>AW</given-names></name><name><surname>Gao</surname><given-names>Y-T</given-names></name><name><surname>Chanock</surname><given-names>SJ</given-names></name><name><surname>Araya</surname><given-names>JC</given-names></name><name><surname>Andersen</surname><given-names>JB</given-names></name><name><surname>Koshiol</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Integrative molecular characterisation of gallbladder cancer reveals micro-environment-associated subtypes</article-title><source>Journal of Hepatology</source><volume>74</volume><fpage>1132</fpage><lpage>1144</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2020.11.033</pub-id><pub-id pub-id-type="pmid">33276026</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nowell</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="1976">1976</year><article-title>The clonal evolution of tumor cell populations</article-title><source>Science</source><volume>194</volume><fpage>23</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1126/science.959840</pub-id><pub-id pub-id-type="pmid">959840</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ochi</surname><given-names>Y</given-names></name><name><surname>Yoshida</surname><given-names>K</given-names></name><name><surname>Huang</surname><given-names>Y-J</given-names></name><name><surname>Kuo</surname><given-names>M-C</given-names></name><name><surname>Nannya</surname><given-names>Y</given-names></name><name><surname>Sasaki</surname><given-names>K</given-names></name><name><surname>Mitani</surname><given-names>K</given-names></name><name><surname>Hosoya</surname><given-names>N</given-names></name><name><surname>Hiramoto</surname><given-names>N</given-names></name><name><surname>Ishikawa</surname><given-names>T</given-names></name><name><surname>Branford</surname><given-names>S</given-names></name><name><surname>Shanmuganathan</surname><given-names>N</given-names></name><name><surname>Ohyashiki</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>N</given-names></name><name><surname>Takaku</surname><given-names>T</given-names></name><name><surname>Tsuchiya</surname><given-names>S</given-names></name><name><surname>Kanemura</surname><given-names>N</given-names></name><name><surname>Nakamura</surname><given-names>N</given-names></name><name><surname>Ueda</surname><given-names>Y</given-names></name><name><surname>Yoshihara</surname><given-names>S</given-names></name><name><surname>Bera</surname><given-names>R</given-names></name><name><surname>Shiozawa</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Takeda</surname><given-names>J</given-names></name><name><surname>Watatani</surname><given-names>Y</given-names></name><name><surname>Okuda</surname><given-names>R</given-names></name><name><surname>Makishima</surname><given-names>H</given-names></name><name><surname>Shiraishi</surname><given-names>Y</given-names></name><name><surname>Chiba</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Sanada</surname><given-names>M</given-names></name><name><surname>Takaori-Kondo</surname><given-names>A</given-names></name><name><surname>Miyano</surname><given-names>S</given-names></name><name><surname>Ogawa</surname><given-names>S</given-names></name><name><surname>Shih</surname><given-names>L-Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>2833</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-23097-w</pub-id><pub-id pub-id-type="pmid">33990592</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ok</surname><given-names>HE</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Shim</surname><given-names>WB</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Bae</surname><given-names>D-H</given-names></name><name><surname>Chung</surname><given-names>D-H</given-names></name><name><surname>Chun</surname><given-names>HS</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Natural occurrence of aflatoxin B1 in marketed foods and risk estimates of dietary exposure in Koreans</article-title><source>Journal of Food Protection</source><volume>70</volume><fpage>2824</fpage><lpage>2828</lpage><pub-id pub-id-type="doi">10.4315/0362-028x-70.12.2824</pub-id><pub-id pub-id-type="pmid">18095437</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roa</surname><given-names>JC</given-names></name><name><surname>García</surname><given-names>P</given-names></name><name><surname>Kapoor</surname><given-names>VK</given-names></name><name><surname>Maithel</surname><given-names>SK</given-names></name><name><surname>Javle</surname><given-names>M</given-names></name><name><surname>Koshiol</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Gallbladder cancer</article-title><source>Nature Reviews. Disease Primers</source><volume>8</volume><elocation-id>70</elocation-id><pub-id pub-id-type="doi">10.1038/s41572-022-00398-y</pub-id><pub-id pub-id-type="pmid">36302789</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>A</given-names></name><name><surname>Khattra</surname><given-names>J</given-names></name><name><surname>Yap</surname><given-names>D</given-names></name><name><surname>Wan</surname><given-names>A</given-names></name><name><surname>Laks</surname><given-names>E</given-names></name><name><surname>Biele</surname><given-names>J</given-names></name><name><surname>Ha</surname><given-names>G</given-names></name><name><surname>Aparicio</surname><given-names>S</given-names></name><name><surname>Bouchard-Côté</surname><given-names>A</given-names></name><name><surname>Shah</surname><given-names>SP</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>PyClone: statistical inference of clonal population structure in cancer</article-title><source>Nature Methods</source><volume>11</volume><fpage>396</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2883</pub-id><pub-id pub-id-type="pmid">24633410</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>MA</given-names></name><name><surname>Nielsen</surname><given-names>CB</given-names></name><name><surname>Chan</surname><given-names>FC</given-names></name><name><surname>McPherson</surname><given-names>A</given-names></name><name><surname>Roth</surname><given-names>A</given-names></name><name><surname>Farahani</surname><given-names>H</given-names></name><name><surname>Machev</surname><given-names>D</given-names></name><name><surname>Steif</surname><given-names>A</given-names></name><name><surname>Shah</surname><given-names>SP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>E-scape: interactive visualization of single-cell phylogenetics and cancer evolution</article-title><source>Nature Methods</source><volume>14</volume><fpage>549</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4303</pub-id><pub-id pub-id-type="pmid">28557980</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turajlic</surname><given-names>S</given-names></name><name><surname>Swanton</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Metastasis as an evolutionary process</article-title><source>Science</source><volume>352</volume><fpage>169</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1126/science.aaf2784</pub-id><pub-id pub-id-type="pmid">27124450</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turajlic</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Litchfield</surname><given-names>K</given-names></name><name><surname>Rowan</surname><given-names>A</given-names></name><name><surname>Chambers</surname><given-names>T</given-names></name><name><surname>Lopez</surname><given-names>JI</given-names></name><name><surname>Nicol</surname><given-names>D</given-names></name><name><surname>O’Brien</surname><given-names>T</given-names></name><name><surname>Larkin</surname><given-names>J</given-names></name><name><surname>Horswell</surname><given-names>S</given-names></name><name><surname>Stares</surname><given-names>M</given-names></name><name><surname>Au</surname><given-names>L</given-names></name><name><surname>Jamal-Hanjani</surname><given-names>M</given-names></name><name><surname>Challacombe</surname><given-names>B</given-names></name><name><surname>Chandra</surname><given-names>A</given-names></name><name><surname>Hazell</surname><given-names>S</given-names></name><name><surname>Eichler-Jonsson</surname><given-names>C</given-names></name><name><surname>Soultati</surname><given-names>A</given-names></name><name><surname>Chowdhury</surname><given-names>S</given-names></name><name><surname>Rudman</surname><given-names>S</given-names></name><name><surname>Lynch</surname><given-names>J</given-names></name><name><surname>Fernando</surname><given-names>A</given-names></name><name><surname>Stamp</surname><given-names>G</given-names></name><name><surname>Nye</surname><given-names>E</given-names></name><name><surname>Jabbar</surname><given-names>F</given-names></name><name><surname>Spain</surname><given-names>L</given-names></name><name><surname>Lall</surname><given-names>S</given-names></name><name><surname>Guarch</surname><given-names>R</given-names></name><name><surname>Falzon</surname><given-names>M</given-names></name><name><surname>Proctor</surname><given-names>I</given-names></name><name><surname>Pickering</surname><given-names>L</given-names></name><name><surname>Gore</surname><given-names>M</given-names></name><name><surname>Watkins</surname><given-names>TBK</given-names></name><name><surname>Ward</surname><given-names>S</given-names></name><name><surname>Stewart</surname><given-names>A</given-names></name><name><surname>DiNatale</surname><given-names>R</given-names></name><name><surname>Becerra</surname><given-names>MF</given-names></name><name><surname>Reznik</surname><given-names>E</given-names></name><name><surname>Hsieh</surname><given-names>JJ</given-names></name><name><surname>Richmond</surname><given-names>TA</given-names></name><name><surname>Mayhew</surname><given-names>GF</given-names></name><name><surname>Hill</surname><given-names>SM</given-names></name><name><surname>McNally</surname><given-names>CD</given-names></name><name><surname>Jones</surname><given-names>C</given-names></name><name><surname>Rosenbaum</surname><given-names>H</given-names></name><name><surname>Stanislaw</surname><given-names>S</given-names></name><name><surname>Burgess</surname><given-names>DL</given-names></name><name><surname>Alexander</surname><given-names>NR</given-names></name><name><surname>Swanton</surname><given-names>C</given-names></name><collab>PEACE</collab><collab>TRACERx Renal Consortium</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Tracking cancer evolution reveals constrained routes to metastases: tracerx renal</article-title><source>Cell</source><volume>173</volume><fpage>581</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.03.057</pub-id><pub-id pub-id-type="pmid">29656895</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turajlic</surname><given-names>S</given-names></name><name><surname>Sottoriva</surname><given-names>A</given-names></name><name><surname>Graham</surname><given-names>T</given-names></name><name><surname>Swanton</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Resolving genetic heterogeneity in cancer</article-title><source>Nature Reviews. Genetics</source><volume>20</volume><fpage>404</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1038/s41576-019-0114-6</pub-id><pub-id pub-id-type="pmid">30918367</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ullah</surname><given-names>I</given-names></name><name><surname>Karthik</surname><given-names>G-M</given-names></name><name><surname>Alkodsi</surname><given-names>A</given-names></name><name><surname>Kjällquist</surname><given-names>U</given-names></name><name><surname>Stålhammar</surname><given-names>G</given-names></name><name><surname>Lövrot</surname><given-names>J</given-names></name><name><surname>Martinez</surname><given-names>N-F</given-names></name><name><surname>Lagergren</surname><given-names>J</given-names></name><name><surname>Hautaniemi</surname><given-names>S</given-names></name><name><surname>Hartman</surname><given-names>J</given-names></name><name><surname>Bergh</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph nodes</article-title><source>The Journal of Clinical Investigation</source><volume>128</volume><fpage>1355</fpage><lpage>1370</lpage><pub-id pub-id-type="doi">10.1172/JCI96149</pub-id><pub-id pub-id-type="pmid">29480816</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valle</surname><given-names>J</given-names></name><name><surname>Wasan</surname><given-names>H</given-names></name><name><surname>Palmer</surname><given-names>DH</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Anthoney</surname><given-names>A</given-names></name><name><surname>Maraveyas</surname><given-names>A</given-names></name><name><surname>Madhusudan</surname><given-names>S</given-names></name><name><surname>Iveson</surname><given-names>T</given-names></name><name><surname>Hughes</surname><given-names>S</given-names></name><name><surname>Pereira</surname><given-names>SP</given-names></name><name><surname>Roughton</surname><given-names>M</given-names></name><name><surname>Bridgewater</surname><given-names>J</given-names></name><collab>ABC-02 Trial Investigators</collab></person-group><year iso-8601-date="2010">2010</year><article-title>Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer</article-title><source>The New England Journal of Medicine</source><volume>362</volume><fpage>1273</fpage><lpage>1281</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0908721</pub-id><pub-id pub-id-type="pmid">20375404</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valle</surname><given-names>JW</given-names></name><name><surname>Kelley</surname><given-names>RK</given-names></name><name><surname>Nervi</surname><given-names>B</given-names></name><name><surname>Oh</surname><given-names>DY</given-names></name><name><surname>Zhu</surname><given-names>AX</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Biliary tract cancer</article-title><source>Lancet</source><volume>397</volume><fpage>428</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00153-7</pub-id><pub-id pub-id-type="pmid">33516341</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Fearon</surname><given-names>ER</given-names></name><name><surname>Hamilton</surname><given-names>SR</given-names></name><name><surname>Kern</surname><given-names>SE</given-names></name><name><surname>Preisinger</surname><given-names>AC</given-names></name><name><surname>Leppert</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>White</surname><given-names>R</given-names></name><name><surname>Smits</surname><given-names>AM</given-names></name><name><surname>Bos</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Genetic alterations during colorectal-tumor development</article-title><source>The New England Journal of Medicine</source><volume>319</volume><fpage>525</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1056/NEJM198809013190901</pub-id><pub-id pub-id-type="pmid">2841597</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wardell</surname><given-names>CP</given-names></name><name><surname>Fujita</surname><given-names>M</given-names></name><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Simbolo</surname><given-names>M</given-names></name><name><surname>Fassan</surname><given-names>M</given-names></name><name><surname>Karlic</surname><given-names>R</given-names></name><name><surname>Polak</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Hatanaka</surname><given-names>Y</given-names></name><name><surname>Maejima</surname><given-names>K</given-names></name><name><surname>Lawlor</surname><given-names>RT</given-names></name><name><surname>Nakanishi</surname><given-names>Y</given-names></name><name><surname>Mitsuhashi</surname><given-names>T</given-names></name><name><surname>Fujimoto</surname><given-names>A</given-names></name><name><surname>Furuta</surname><given-names>M</given-names></name><name><surname>Ruzzenente</surname><given-names>A</given-names></name><name><surname>Conci</surname><given-names>S</given-names></name><name><surname>Oosawa</surname><given-names>A</given-names></name><name><surname>Sasaki-Oku</surname><given-names>A</given-names></name><name><surname>Nakano</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Yamamoto</surname><given-names>Y</given-names></name><name><surname>Michiaki</surname><given-names>K</given-names></name><name><surname>Kawakami</surname><given-names>Y</given-names></name><name><surname>Aikata</surname><given-names>H</given-names></name><name><surname>Ueno</surname><given-names>M</given-names></name><name><surname>Hayami</surname><given-names>S</given-names></name><name><surname>Gotoh</surname><given-names>K</given-names></name><name><surname>Ariizumi</surname><given-names>S-I</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Yamaue</surname><given-names>H</given-names></name><name><surname>Chayama</surname><given-names>K</given-names></name><name><surname>Miyano</surname><given-names>S</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Scarpa</surname><given-names>A</given-names></name><name><surname>Hirano</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Nakagawa</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations</article-title><source>Journal of Hepatology</source><volume>68</volume><fpage>959</fpage><lpage>969</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2018.01.009</pub-id><pub-id pub-id-type="pmid">29360550</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>Q</given-names></name><name><surname>Ye</surname><given-names>Z</given-names></name><name><surname>Zhong</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Myers</surname><given-names>RE</given-names></name><name><surname>Palazzo</surname><given-names>JP</given-names></name><name><surname>Fortuna</surname><given-names>D</given-names></name><name><surname>Yan</surname><given-names>A</given-names></name><name><surname>Waldman</surname><given-names>SA</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Posey</surname><given-names>JA</given-names></name><name><surname>Basu-Mallick</surname><given-names>A</given-names></name><name><surname>Jiang</surname><given-names>BH</given-names></name><name><surname>Hou</surname><given-names>L</given-names></name><name><surname>Shu</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Xing</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Multiregion whole-exome sequencing of matched primary and metastatic tumors revealed genomic heterogeneity and suggested polyclonal seeding in colorectal cancer metastasis</article-title><source>Annals of Oncology</source><volume>28</volume><fpage>2135</fpage><lpage>2141</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdx278</pub-id><pub-id pub-id-type="pmid">28911083</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolff</surname><given-names>AC</given-names></name><name><surname>Hammond</surname><given-names>MEH</given-names></name><name><surname>Allison</surname><given-names>KH</given-names></name><name><surname>Harvey</surname><given-names>BE</given-names></name><name><surname>Mangu</surname><given-names>PB</given-names></name><name><surname>Bartlett</surname><given-names>JMS</given-names></name><name><surname>Bilous</surname><given-names>M</given-names></name><name><surname>Ellis</surname><given-names>IO</given-names></name><name><surname>Fitzgibbons</surname><given-names>P</given-names></name><name><surname>Hanna</surname><given-names>W</given-names></name><name><surname>Jenkins</surname><given-names>RB</given-names></name><name><surname>Press</surname><given-names>MF</given-names></name><name><surname>Spears</surname><given-names>PA</given-names></name><name><surname>Vance</surname><given-names>GH</given-names></name><name><surname>Viale</surname><given-names>G</given-names></name><name><surname>McShane</surname><given-names>LM</given-names></name><name><surname>Dowsett</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Human epidermal growth factor receptor 2 testing in breast cancer: American Society of clinical oncology/college of American pathologists clinical practice guideline focused update</article-title><source>Archives of Pathology &amp; Laboratory Medicine</source><volume>142</volume><fpage>1364</fpage><lpage>1382</lpage><pub-id pub-id-type="doi">10.5858/arpa.2018-0902-SA</pub-id><pub-id pub-id-type="pmid">29846104</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Tan</surname><given-names>M</given-names></name><name><surname>Xiong</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The β-trcp-FBXW2-SKP2 axis regulates lung cancer cell growth with FBXW2 acting as a tumour suppressor</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>14002</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms14002</pub-id><pub-id pub-id-type="pmid">28090088</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yachida</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Bozic</surname><given-names>I</given-names></name><name><surname>Antal</surname><given-names>T</given-names></name><name><surname>Leary</surname><given-names>R</given-names></name><name><surname>Fu</surname><given-names>B</given-names></name><name><surname>Kamiyama</surname><given-names>M</given-names></name><name><surname>Hruban</surname><given-names>RH</given-names></name><name><surname>Eshleman</surname><given-names>JR</given-names></name><name><surname>Nowak</surname><given-names>MA</given-names></name><name><surname>Velculescu</surname><given-names>VE</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Iacobuzio-Donahue</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Distant metastasis occurs late during the genetic evolution of pancreatic cancer</article-title><source>Nature</source><volume>467</volume><fpage>1114</fpage><lpage>1117</lpage><pub-id pub-id-type="doi">10.1038/nature09515</pub-id><pub-id pub-id-type="pmid">20981102</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Xiong</surname><given-names>W</given-names></name><name><surname>McCarthy</surname><given-names>JB</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Xiang</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The NOR1/OSCP1 proteins in cancer: from epigenetic silencing to functional characterization of a novel tumor suppressor</article-title><source>Journal of Cancer</source><volume>8</volume><fpage>626</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.7150/jca.17579</pub-id><pub-id pub-id-type="pmid">28367242</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokoyama</surname><given-names>A</given-names></name><name><surname>Kakiuchi</surname><given-names>N</given-names></name><name><surname>Yoshizato</surname><given-names>T</given-names></name><name><surname>Nannya</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Takeuchi</surname><given-names>Y</given-names></name><name><surname>Shiozawa</surname><given-names>Y</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Aoki</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>SK</given-names></name><name><surname>Fujii</surname><given-names>Y</given-names></name><name><surname>Yoshida</surname><given-names>K</given-names></name><name><surname>Kataoka</surname><given-names>K</given-names></name><name><surname>Nakagawa</surname><given-names>MM</given-names></name><name><surname>Inoue</surname><given-names>Y</given-names></name><name><surname>Hirano</surname><given-names>T</given-names></name><name><surname>Shiraishi</surname><given-names>Y</given-names></name><name><surname>Chiba</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Sanada</surname><given-names>M</given-names></name><name><surname>Nishikawa</surname><given-names>Y</given-names></name><name><surname>Amanuma</surname><given-names>Y</given-names></name><name><surname>Ohashi</surname><given-names>S</given-names></name><name><surname>Aoyama</surname><given-names>I</given-names></name><name><surname>Horimatsu</surname><given-names>T</given-names></name><name><surname>Miyamoto</surname><given-names>S</given-names></name><name><surname>Tsunoda</surname><given-names>S</given-names></name><name><surname>Sakai</surname><given-names>Y</given-names></name><name><surname>Narahara</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>JB</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Sawada</surname><given-names>G</given-names></name><name><surname>Mimori</surname><given-names>K</given-names></name><name><surname>Minamiguchi</surname><given-names>S</given-names></name><name><surname>Haga</surname><given-names>H</given-names></name><name><surname>Seno</surname><given-names>H</given-names></name><name><surname>Miyano</surname><given-names>S</given-names></name><name><surname>Makishima</surname><given-names>H</given-names></name><name><surname>Muto</surname><given-names>M</given-names></name><name><surname>Ogawa</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Age-Related remodelling of oesophageal epithelia by mutated cancer drivers</article-title><source>Nature</source><volume>565</volume><fpage>312</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0811-x</pub-id><pub-id pub-id-type="pmid">30602793</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>JG</given-names></name><name><surname>Kim</surname><given-names>MH</given-names></name><name><surname>Jang</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Hwang</surname><given-names>HK</given-names></name><name><surname>Kang</surname><given-names>CM</given-names></name><name><surname>Lee</surname><given-names>WJ</given-names></name><name><surname>Kang</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>CK</given-names></name><name><surname>Lee</surname><given-names>MG</given-names></name><name><surname>Chung</surname><given-names>HC</given-names></name><name><surname>Choi</surname><given-names>HJ</given-names></name><name><surname>Park</surname><given-names>YN</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Molecular characterization of biliary tract cancer predicts chemotherapy and programmed death 1/programmed death-ligand 1 blockade responses</article-title><source>Hepatology</source><volume>74</volume><fpage>1914</fpage><lpage>1931</lpage><pub-id pub-id-type="doi">10.1002/hep.31862</pub-id><pub-id pub-id-type="pmid">33884649</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Pkcdelta signaling: mechanisms of DNA damage response and apoptosis</article-title><source>Cellular Signalling</source><volume>19</volume><fpage>892</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2007.01.027</pub-id><pub-id pub-id-type="pmid">17336499</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Mishra</surname><given-names>L</given-names></name><name><surname>Deng</surname><given-names>CX</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The role of TGF-β/SMAD4 signaling in cancer</article-title><source>International Journal of Biological Sciences</source><volume>14</volume><fpage>111</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.7150/ijbs.23230</pub-id><pub-id pub-id-type="pmid">29483830</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.78636.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Turajlic</surname><given-names>Samra</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04tnbqb63</institution-id><institution>The Francis Crick Institute</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.03.31.486530" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.03.31.486530"/></front-stub><body><p>This is the first dedicated study of clonal evolution in gallbladder cancer that involves precancerous, transformed primary and metastatic lesions. The main insights include the finding of subclonal diversity in precancerous lesions, a degree of bottlenecking during transformation but maintenance of some clonal complexity through metastases.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.78636.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Turajlic</surname><given-names>Samra</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04tnbqb63</institution-id><institution>The Francis Crick Institute</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Raghavan</surname><given-names>Srivatsan</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02jzgtq86</institution-id><institution>Dana-Farber Cancer Institute</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.03.31.486530">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.03.31.486530v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Gallbladder adenocarcinomas undergo subclonal diversification and selection from precancerous lesions to metastatic tumors&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and W Kimryn Rathmell as the Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Srivatsan Raghavan (Reviewer #1).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>Please answer reviewers' comments. Overall:</p><p>1. Please give inclusion, exclusion, and sample selection criteria indicating which are fresh frozen, which are FFPE and how many samples and sample types are included for each patient. Also samples sites and types of samples. (Surgical vs biopsy).</p><p>2. Please clarify the presentation of data and figures.</p><p>3. Please explain how you accounted for intratumour heterogeneity.</p><p>4. Please describe reconstructing clonal phylogenies and how you dealt with multiple samples per patient.</p><p>5. Please analyse FFPE samples with the appropriate adjustments for noise relative to fresh frozen.</p><p>6. Please discuss the seeming variation in results of mutational signature analysis as quoted in the abstract versus those in Figure 4.</p><p>7. Please re-consider the inference of met-met spread and whether it is really supported by the data.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>1. In Figure 1A, it would be helpful to indicate the site of disease associated with each tissue sample, and also to indicate which specimens were biopsies versus resection tissue.</p><p>2. As discussed above in the public review, the authors show variation across different sites of disease and across time, but it is somewhat difficult to distinguish between these in the figures. It would be helpful if Figures 2 and 3 could more clearly distinguish between spatial and temporal variation in clonality, particularly in terms of tracing and more effectively visualizing clonal variation across space versus over time. In addition, the authors don't comment on genomic variation in relation to intervening therapy, and this would be helpful particularly if any notable patterns were observed that may have clinical implications.</p><p>3. P. 6, lines 7-11 – In patients with concurrent BilIN and GBAC in the same gall bladder resection specimen, how were these identified? Were these lesions observed by a pathologist in different locations and each isolated separately? Additional details in the methods section would be helpful in this regard.</p><p>4. P.8, lines 16-20 – &quot;The metastatic lesions were uniformly polyclonal. In GB-A1, GB-A2, and GB-S4, which contained two or more distant metastatic lesions, the clonal compositions of metastatic lesions were heterogeneous. However, metastatic lesions in one organ or adjacent organs showed similar clonal compositions. In GB-A1 (Figure 2A), abdominal wall 1-4 did not contain clone C, and liver 1-3 did not contain clone F.&quot; These statements seem contradictory, particularly the statement referring to &quot;similar clonal compositions&quot; and the following one which provides a counterexample. The conclusion that metastatic lesions in nearby organs are similar is only supported by a few cases and it is unclear that the authors are really powered to state this definitively.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.78636.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>Please answer reviewers' comments. Overall:</p><p>1. Please give inclusion, exclusion, and sample selection criteria indicating which are fresh frozen, which are FFPE and how many samples and sample types are included for each patient. Also samples sites and types of samples. (Surgical vs biopsy).</p></disp-quote><p>Thank you for the important comment.</p><p>1) We have added the inclusion criteria to the Methods section (Page 15, Line 3-7). There were no specific exclusion criteria and all the obtained samples from the participants were analyzed.</p><p>2) A total of 15 samples obtained by rapid autopsy were fresh-frozen, and 43 samples obtained by surgery or biopsy were formalin-fixed paraffin-embedded (FFPE) specimens. We mentioned this in the Results section (Page 5, Line 8-10).</p><p>3) We revised Supplementary File 1A. The number of samples, methods for sample acquisition (autopsy vs. surgery vs. biopsy), and type of sample (fresh-frozen vs. FFPE) per each patient are now shown in Supplementary File 1A.</p><disp-quote content-type="editor-comment"><p>2. Please clarify the presentation of data and figures.</p></disp-quote><p>Thank you for your advice. Throughout the revision process, meaningful updates were made, and as a result, the presentation of the data and figures has been made clearer. The important changes are summarized below.</p><p>– In Figure 1A, the anatomical information of the obtained samples has been indicated.</p><p>– In Figure 1B, the distinction between the tumor suppressor gene and oncogene was removed.</p><p>– In Figures 2 and 3, the time point at which the tissue was obtained and the anatomical location of the tissue are clearly separated.</p><p>– Figure 4B was moved to Figure 4—figure supplement 2.</p><disp-quote content-type="editor-comment"><p>3. Please explain how you accounted for intratumour heterogeneity.</p></disp-quote><p>Thank you for the important comment. The cellular prevalence of the truncal clone – clone A in every sample – was assumed to be 1.0, and the relative cellular prevalence of the remaining subclones was calculated. The relative proportions of multiple clones were visualized using MapScape and TimeScape (Smith MA et al., Nat Methods. 2017). In Figures 2 and 3, the clonal composition varied from sample to sample, and this is the intratumoral heterogeneity identified in our study.</p><disp-quote content-type="editor-comment"><p>4. Please describe reconstructing clonal phylogenies and how you dealt with multiple samples per patient.</p></disp-quote><p>Thank you for the constructive comment. CITUP (Malikic S et al., Bioinformatics. 2015) infers clonal populations and their frequencies while satisfying phylogenetic constraints and can exploit data from multiple samples. In our study, phylogenetic trees were constructed using the CITUP (0.1.0) command, ‘run_citup_qip.py’. We mentioned this in the Methods section (Page 16, Line 23 – Page 17, Line 1).</p><disp-quote content-type="editor-comment"><p>5. Please analyse FFPE samples with the appropriate adjustments for noise relative to fresh frozen.</p></disp-quote><p>We appreciate your valuable comment. According to previous literature (Chen G et al., Mol Diagn Ther. 2014, Moore DA et al., ESMO Open. 2019), sequencing artifacts induced by formalin fixation satisfy the following conditions: (1) sample specific mutations, (2) C:G &gt; T:A variants, and (3) VAF &lt; 5%. We summarized the mutations satisfying the above conditions in <xref ref-type="table" rid="sa2table1">Author response table 1</xref> (for review only). However, we did not remove these mutations in the analysis of the FFPE samples due to the following reasons: (1) it was impossible to determine which mutation is actual noise by formalin fixation, and (2) sample-specific subclones still existed with little influence on the phylogenetic tree structure even after all the potential artifacts have been eliminated.</p><table-wrap id="sa2table1" position="float"><label>Author response table 1.</label><caption><title>Proportion of mutations satisfying the conditions: (1) C:G &gt; T:A variants, and (2) VAF &lt; 5% in sample-specific clusters.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Patient ID</th><th align="left" valign="top">Sample</th><th align="left" valign="top">Type of sample</th><th align="left" valign="top">Sample specific clusters<sup>*</sup></th><th align="left" valign="top">Number of mutations in sample-specific clusters<sup>†</sup></th><th align="left" valign="top">Number of filtered mutations in sample-specific clusters</th><th align="left" valign="top">Percentage (%)</th></tr></thead><tbody><tr><td align="left" valign="top">GB-A1</td><td align="left" valign="top">BilIN</td><td align="left" valign="top">FFPE</td><td align="left" valign="top">2</td><td align="left" valign="top">34</td><td align="left" valign="top">3</td><td align="left" valign="top">8.8</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">CBD</td><td align="left" valign="top">FFPE</td><td align="left" valign="top">3</td><td align="left" valign="top">121</td><td align="left" valign="top">13</td><td align="left" valign="top">10.7</td></tr><tr><td align="left" valign="top">GB-S1</td><td align="left" valign="top">BilIN</td><td align="left" valign="top">FFPE</td><td align="left" valign="top">2</td><td align="left" valign="top">9</td><td align="left" valign="top">3</td><td align="left" valign="top">33.3</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">GB</td><td align="left" valign="top">FFPE</td><td align="left" valign="top">4</td><td align="left" valign="top">18</td><td align="left" valign="top">7</td><td align="left" valign="top">38.9</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">Distant LN</td><td align="left" valign="top">FFPE</td><td align="left" valign="top">7</td><td align="left" valign="top">6</td><td align="left" valign="top">0</td><td align="left" valign="top">0.0</td></tr><tr><td align="left" valign="top">GB-S2</td><td align="left" valign="top">BilIN</td><td align="left" valign="top">FFPE</td><td align="left" valign="top">6</td><td align="left" valign="top">8</td><td align="left" valign="top">3</td><td align="left" valign="top">37.5</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">GB</td><td align="left" valign="top">FFPE</td><td align="left" valign="top">0</td><td align="left" valign="top">7</td><td align="left" valign="top">2</td><td align="left" valign="top">28.6</td></tr><tr><td align="left" valign="top">GB-S3</td><td align="left" valign="top">BilIN</td><td align="left" valign="top">FFPE</td><td align="left" valign="top">3</td><td align="left" valign="top">7</td><td align="left" valign="top">1</td><td align="left" valign="top">14.3</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">GB</td><td align="left" valign="top">FFPE</td><td align="left" valign="top">2</td><td align="left" valign="top">3</td><td align="left" valign="top">0</td><td align="left" valign="top">0.0</td></tr><tr><td align="left" valign="top">GB-A2</td><td align="left" valign="top">GB</td><td align="left" valign="top">Fresh-frozen</td><td align="left" valign="top">2</td><td align="left" valign="top">40</td><td align="left" valign="top">0</td><td align="left" valign="top">0.0</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">Lung (old)</td><td align="left" valign="top">FFPE</td><td align="left" valign="top">10</td><td align="left" valign="top">17</td><td align="left" valign="top">1</td><td align="left" valign="top">5.9</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">Lung</td><td align="left" valign="top">Fresh-frozen</td><td align="left" valign="top">5</td><td align="left" valign="top">15</td><td align="left" valign="top">0</td><td align="left" valign="top">0.0</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">Chest wall</td><td align="left" valign="top">Fresh-frozen</td><td align="left" valign="top">3</td><td align="left" valign="top">23</td><td align="left" valign="top">0</td><td align="left" valign="top">0.0</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">Liver</td><td align="left" valign="top">Fresh-frozen</td><td align="left" valign="top">4</td><td align="left" valign="top">31</td><td align="left" valign="top">0</td><td align="left" valign="top">0.0</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">Mesentery</td><td align="left" valign="top">Fresh-frozen</td><td align="left" valign="top">6</td><td align="left" valign="top">8</td><td align="left" valign="top">2</td><td align="left" valign="top">25.0</td></tr><tr><td align="left" valign="top">GB-S4</td><td align="left" valign="top">Colon wall</td><td align="left" valign="top">FFPE</td><td align="left" valign="top">3</td><td align="left" valign="top">36</td><td align="left" valign="top">0</td><td align="left" valign="top">0.0</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">Distant LN</td><td align="left" valign="top">FFPE</td><td align="left" valign="top">1</td><td align="left" valign="top">9</td><td align="left" valign="top">2</td><td align="left" valign="top">22.2</td></tr><tr><td align="left" valign="top">GB-S5</td><td align="left" valign="top">GB</td><td align="left" valign="top">FFPE</td><td align="left" valign="top">3</td><td align="left" valign="top">13</td><td align="left" valign="top">0</td><td align="left" valign="top">0.0</td></tr><tr><td align="left" valign="top">GB-S6</td><td align="left" valign="top">GB</td><td align="left" valign="top">FFPE</td><td align="left" valign="top">1</td><td align="left" valign="top">5</td><td align="left" valign="top">0</td><td align="left" valign="top">0.0</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">Lung</td><td align="left" valign="top">FFPE</td><td align="left" valign="top">2</td><td align="left" valign="top">7</td><td align="left" valign="top">0</td><td align="left" valign="top">0.0</td></tr><tr><td align="left" valign="top">GB-S7</td><td align="left" valign="top">GB</td><td align="left" valign="top">FFPE</td><td align="left" valign="top">0</td><td align="left" valign="top">11</td><td align="left" valign="top">0</td><td align="left" valign="top">0.0</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">Regional LN</td><td align="left" valign="top">FFPE</td><td align="left" valign="top">3</td><td align="left" valign="top">5</td><td align="left" valign="top">0</td><td align="left" valign="top">0.0</td></tr><tr><td align="left" valign="top">GB-S8</td><td align="left" valign="top">GB</td><td align="left" valign="top">FFPE</td><td align="left" valign="top">2</td><td align="left" valign="top">35</td><td align="left" valign="top">4</td><td align="left" valign="top">11.4</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">Regional LN</td><td align="left" valign="top">FFPE</td><td align="left" valign="top">0</td><td align="left" valign="top">81</td><td align="left" valign="top">3</td><td align="left" valign="top">3.7</td></tr></tbody></table></table-wrap><p>In FFPE samples, sample-specific mutations were found in 11 of 31 samples (35.5%). The number of possible artifacts satisfying the conditions was median 1/sample (range, 0–13/sample), and their proportion among sample-specific mutations was median 5.9% (range, 0–38.9%). In fresh frozen samples, sample-specific mutations were identified in 1 of 14 samples (7.1%). The number of mutations satisfying the conditions was 2, and their proportion among sample-specific mutations was 25%. Although the number of mutations satisfying the artifact conditions was higher in the FFPE samples than in the fresh frozen samples, there is no definitive way to determine which of these is real noise induced by formalin fixation. In addition, there was no sample-specific subclone consisting merely of mutations satisfying the above conditions.</p><p>BilIN, biliary intraepithelial neoplasia, GB, gallbladder; LN, lymph node; CBD, common bile duct; FFPE, formalin-fixed paraffin-embedded.</p><p><sup>*</sup>See Figure 1—figure supplement 1.</p><p><sup>†</sup>See Supplementary File 2.</p><p>References for Essential Revisions #5</p><p>Chen G, Mosier S, Gocke CD, Lin MT, Eshleman JR. Cytosine deamination is a major cause of baseline noise in next-generation sequencing. Mol Diagn Ther. 2014;18(5):587-93.</p><p>Moore DA, Kushnir M, Mak G, Winter H, Curiel T, Voskoboynik M, et al. Prospective analysis of 895 patients on a UK Genomics Review Board. ESMO Open. 2019;4(2):e000469.</p><disp-quote content-type="editor-comment"><p>6. Please discuss the seeming variation in results of mutational signature analysis as quoted in the abstract versus those in Figure 4.</p></disp-quote><p>Thank you for the important comment. The sentences about mutational signatures in the abstract were a summary of Figure 4C and had been properly described. If Figure 4B confused you, we sincerely apologize to you for any possible misunderstandings. As stated in the manuscript, Figure 4B denotes mutational signature analysis according to the 4 types of samples (BilIN, GB, regional LN metastasis, and distant metastasis) while Figure 4C indicates the analyzed results according to the timing of development during clonal evolution (early carcinogenesis, late carcinogenesis, and metastasis). We suggest that the criterion of Figure 4C makes more sense considering the evolutionary trajectories in cancers. To avoid confusion, we moved Figure 4B to Figure 4—figure supplement 2 and revised the phrase &quot;developmental stages of cancer&quot; to &quot;type of sample&quot; in this figure.</p><disp-quote content-type="editor-comment"><p>7. Please re-consider the inference of met-met spread and whether it is really supported by the data.</p></disp-quote><p>Thank you for the important comment. We agree with reviewer #1's comment 3 that the rationale for metastasis-to-metastasis spread for GB-A1 is weak. Hence, this part was removed from the manuscript.</p><p>However, our data still suggests that the possibility of metastasis-to-metastasis spread is shown in GB-A2. In GB-A2, clone F, which is not present in GB, is dominant in the liver and mesentery, and this finding can be evidence of metastasis-to-metastasis. In addition, the clonal composition of GB is different from those of the lung and chest wall, while the clonal composition of the lung and chest wall is similar.</p><p>For this part, Figure 3A and its description in the manuscript have been updated (Page 12, Line 9-12).</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>1. In Figure 1A, it would be helpful to indicate the site of disease associated with each tissue sample, and also to indicate which specimens were biopsies versus resection tissue.</p></disp-quote><p>Thank you for the important comment. Reflecting on your comment, the anatomical information of the obtained samples has been updated in Figure 1A. As you can check by combining the color of the box (Surgery or Autopsy) and '' mark in Figure 1A, all were resection samples from surgery or autopsy except for the liver tissue of GB-S5 (biopsy). In addition, information on whether the tissue was obtained by resection or biopsy was added to Supplementary File 1A.</p><disp-quote content-type="editor-comment"><p>2. As discussed above in the public review, the authors show variation across different sites of disease and across time, but it is somewhat difficult to distinguish between these in the figures. It would be helpful if Figures 2 and 3 could more clearly distinguish between spatial and temporal variation in clonality, particularly in terms of tracing and more effectively visualizing clonal variation across space versus over time. In addition, the authors don't comment on genomic variation in relation to intervening therapy, and this would be helpful particularly if any notable patterns were observed that may have clinical implications.</p></disp-quote><p>Thank you for the important comment about (1) figures and (2) genomic variation about intervening therapy.</p><p>1) We have modified Figures 2 and 3 to distinguish between spatial and temporal variation more clearly.</p><p>2) Although it would have been better to compare genetic variation before and after treatment, especially when targeted therapies are used, only 2 out of 11 patients received targeted agents in our cohort. The GB-A1 patient was treated with varlitinib, both an <italic>EGFR</italic> and <italic>HER2</italic> inhibitor, and then ceralasertib, which targets the DNA damage repair pathway. There was no difference in <italic>HER2</italic> copy number before and after using varlitinib (Figure 2A). The number of mutations before the administration of ceralasertib was a median of 49 (range, 44–52), and the number of mutations after administration was a median of 60 (range, 48–104). However, it is difficult to conclude that the increased number of mutations was caused by ceralasertib because the administration period was as short as 2 months and the number of patients was only one. The GB-A2 patient was treated with a RON receptor tyrosine kinase inhibitor. After treatment, clone F containing <italic>PRKCD</italic> p.I153L expanded. However, it is difficult to give meaning to a single clinical case. Nevertheless, we agree with your opinion that we can get more clinical insights from sequencing multiple specimens before and after treatment.</p><disp-quote content-type="editor-comment"><p>3. P. 6, lines 7-11 – In patients with concurrent BilIN and GBAC in the same gall bladder resection specimen, how were these identified? Were these lesions observed by a pathologist in different locations and each isolated separately? Additional details in the methods section would be helpful in this regard.</p></disp-quote><p>Thank you for the constructive comment. Our board-certified pathologists (Prof. Soomin Ahn and Hee Young Na) identified and dissected BilIN and GBAC lesions from tissue slides. We added this information to the Method section (Page 15, Line 8-9).</p><disp-quote content-type="editor-comment"><p>4. P.8, lines 16-20 – &quot;The metastatic lesions were uniformly polyclonal. In GB-A1, GB-A2, and GB-S4, which contained two or more distant metastatic lesions, the clonal compositions of metastatic lesions were heterogeneous. However, metastatic lesions in one organ or adjacent organs showed similar clonal compositions. In GB-A1 (Figure 2A), abdominal wall 1-4 did not contain clone C, and liver 1-3 did not contain clone F.&quot; These statements seem contradictory, particularly the statement referring to &quot;similar clonal compositions&quot; and the following one which provides a counterexample. The conclusion that metastatic lesions in nearby organs are similar is only supported by a few cases and it is unclear that the authors are really powered to state this definitively.</p></disp-quote><p>We agree with your important comment. The contradictory and unclear sentences were corrected to convey the meaning accurately, and the overall statement was softened:</p><p>&quot;The metastatic lesions were uniformly polyclonal. In GB-A1, GB-A2, and GB-S4, which contained two or more distant metastatic lesions, the clonal composition of tissues obtained from the same or adjacent organs showed a similar tendency, while the clonal composition of anatomically distant organs was distinct from each other.&quot; (Page 8, Line 13-16)</p></body></sub-article></article>